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ABSTRACT 
 
Breast cancer is the most common malignancy diagnosed among women and is the first cause 
of neoplastic death in women globally. In the last decade our understanding of breast cancer 
biology has increased and led to the development of a number of targeted therapies, one of which 
is targeting the cell apoptosis pathway. One of the new targeting pathways under investigation, 
which was found to be involved in both cell apoptosis and cell proliferation processes, is the 
sphingolipid signalling pathway. The sphingolipid pathway represents a group of intracellular 
and extracellular bioactive lipid molecules, including ceramide, ceramide- 1-phosphate, 
sphingosine, and sphingosine-1-phosphate (S1P). In my research, I focused on the role S1P plays 
in breast cancer and its potential application as a therapeutic agent. I examined the effects of S1P 
on the apoptosis, proliferation, and cytotoxicity of different types of breast cancer cell lines in 
vitro. In addition, I evaluated the effect of both low and high doses of S1P when co-
administrated with anticancer drugs commonly used in breast cancer treatment in vitro and in 
vivo. Moreover, I studied the S1P cellular distribution following exogenous administration. My 
results demonstrate that S1P can selectively induce apoptosis in breast cancer cells without 
harming normal breast cells and that S1P is more effective against aggressive breast cancer cells. 
Another major finding of my study is that S1P can increase the efficacy of chemotherapies 
against human breast cancer cells. Although S1P cannot directly substitute the current 
chemotherapies, S1P may function as a good candidate for combination therapy. Furthermore, 
my work showed that the pro-apoptotic and anti-proliferative effect of S1P is correlated with its 
intracellular action and that chronic exposure of exogenous S1P in vivo is not toxic to the major 
organs. Certainly, S1P inclusion in breast cancer treatment modalities may decrease the 
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morbidity and mortality of breast cancer patients and improve clinical outcomes. Further 
investigations are required to understand the mechanism by which S1P induces apoptosis and 
inhibits cell proliferation.   
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1.  LITERATURE REVIEW:  
1.1.   BREAST CANCER 
 1.1.1. INTRODUCTION 
     Breast cancer is the most common malignancy diagnosed among women in both developed 
and developing countries and is the first cause of neoplastic death in women globally. According 
to global cancer statistics published by the International Agency of Research on cancer (IARC) 
of the World Health Organization (WHO), breast cancer incidence approximated 1,384,155 cases 
worldwide in 2008 and the estimated number of deaths in the same year was around 458,503 
cases (Figure 1). The causes of breast cancer remain unknown in most patients but studies have 
found a number of risk factors that contribute to its development (Kumar & Clark, 2002, p. 474). 
It is well known that breast cancer, like other neoplastic diseases, is a result of a genetic mutation 
that leads to abnormalities in the cell cycle progression, differentiation, apoptosis, proliferation, 
growth signalling, DNA repair, and DNA damage (Kumar & Clark, 2002, p. 474). Today, due to 
advances in molecular biology, a number of molecular pathways that correlate with breast cancer 
development have been identified, and based on such research, new targeting therapies have 
been developed to decrease the breast cancer mortality rate and to improve the patient clinical 
outcomes.   
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Figure 1. Cancer incidence and mortality rate among women worldwide according to the 2008 
global cancer statistics published by International Agency of Research on cancer (IARC) of the 
World Health Organization (WHO). Breast cancer has the highest incidence rate in women 
compared to other types of cancer and is the primary cause of death.  
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1.1.2. ETIOLOGY AND EPIDEMIOLOGY 
 According to the World Cancer Report of 2008 published by WHO, the incidence of breast 
cancer is high in North America, South America, Europe and Australia; and the lowest rates are 
recorded in most countries of sub-Saharan Africa, China, and Eastern Asia, except Japan. These 
statistics suggest that breast cancer development is associated with environmental factors that 
vary in different countries and regions. In addition, the variations between Eastern and Western 
lifestyles and diets could play a major role in breast cancer development. Several risk factors are 
associated with breast cancer development (Jones & Burris-III, 2000, p.1771). These risk factors 
can be divided into three categories: environmental, genetic and endocrinal (Jones & Burris-III, 
2000, p.1769). 
The dietary differences between the East and West, especially related to the consumption of 
fat, could be a link to the higher incidence of breast cancer in Western countries compared with 
Eastern countries (Jones & Burris-III, 2000, p.1771). Consumption of a high fat diet will increase 
the risk of developing breast cancer (Jones & Burris-III, 2000, p.1771). Also, obesity, which is 
more common in Western countries than Eastern countries, could be a contributor to the higher 
incidence of breast cancer in Western countries. Obesity increases the estrogen level and causes 
alterations in glucose metabolism, which in turn increases the risk of developing breast cancer 
(Jones & Burris-III, 2000, p.1771). In addition, people who smoke tobacco and consume alcohol 
are at a higher risk of developing breast cancer (Jones & Burris-III, 2000, p.1771). 
Family history is an important risk factor for breast cancer development. Women with a first-
degree relative (i.e., mother or sister) with breast cancer have a higher probability of developing 
breast cancer compared with women who do not have relatives with breast cancer (Jones & 
Burris-III, 2000, p.1769). In addition, women who carry BRCA1 and BRCA2 gene mutation are 
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at a higher risk and they should be encouraged to educate themselves and practice early detection 
methods (i.e., self-examination and annual mammography) (Jones & Burris-III, 2000, p.1769). 
Women who have fibrocystic disease or fibroadenoma of the breast are at higher risk and need 
close monitoring for breast cancer development (Jones & Burris-III, 2000, p.1770). 
 Exposure to exogenous hormones (i.e., oral contraceptive or hormonal replacement therapy) 
will increase the risk for breast cancer development. This is because estrogen promotes the 
growth of breast cells and significant clinical evidence links estrogen administration and breast 
cancer development (Jones & Burris-III, 2000, p.1770). In addition, women who have early 
menarche (i.e., before the age of 12), late menopause (i.e., after the age of 55), or late first full-
term pregnancy (i.e., after the age of 35) are at a higher risk (Jones & Burris-III, 2000, p.1770). 
However, it has been found that pregnancy and lactation could play protective role against breast 
cancer development (Jones & Burris-III, 2000, p.1770). 
1.1.3. BREAST CANCER BIOLOGY 
1.1.3.1. ANATOMY OF HUMAN BREAST 
 Breasts are complex organs composed of skin, connective tissue, fatty tissue, a branching 
duct system, abundant blood supply, an extensive lymphatic network, nerves and a glandular 
structure (Lindley & Michaud, 2005, p.2334). However, the three major components are the 
mammary gland, the connective tissue and the fatty tissue or adipose tissue (McCool, Stone-
Candry & Bradford, 1998). The mammary gland is the functional element of the breast; it is 
composed of lobules and ducts that are lined with epithelial cells, the milk producing cells of the 
breast (McCool, Stone-Candry & Bradford, 1998). The connective tissue and the adipose tissue 
are the structural components of the breast; they give the breast its shape (McCool, Stone-Candry 
& Bradford, 1998). The arterial and venous system supply the breast with blood; the superficial 
 5 
 
and the deeper blood vessels are usually connected with channels of lymphatic system (McCool, 
Stone-Candry & Bradford, 1998). The primary breast lymph is drained initially into the axillary 
node and the additional lymph will drain at the parasternal node (McCool, Stone-Candry & 
Bradford, 1998). 
 At the time of puberty, women’s breasts start to develop under the influence of the sex 
hormones (Jones & Burris-III, 2000, p.1771). However, breast development during puberty is 
limited and full growth of the breast occurs during the first full-term pregnancy (Jones & Burris-
III, 2000, p.1771). The development and function of the breast are controlled by both the 
pituitary gland and the ovaries (McCool, Stone-Candry & Bradford, 1998). The pituitary gland 
will release the follicle stimulating hormone (FSH) and the luteinizing hormone (LH) that will 
stimulate the ovaries to release estrogen and progesterone. These hormones will facilitate breast 
growth and development. Prolactin hormone (PRL), which is released by the pituitary gland, also 
plays a role in breast cancer function and development (McCool, Stone-Candry & Bradford, 
1998). Breasts have a great variation in the anatomical presentation and physiological 
development (McCool, Stone-Candry & Bradford, 1998). Healthy female breasts are seldom 
symmetrical in both shape and size; usually, the left breast is slightly larger than the right breast 
(McCool, Stone-Candry & Bradford, 1998). At the onset of menses the breast are largest in size 
and the smallest in day 4 or 7 of the menstrual cycle (McCool, Stone-Candry & Bradford, 1998). 
The breast change in size and shape occurs also during pregnancy and lactation (McCool, Stone-
Candry & Bradford, 1998) 
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1.1.3.2. BREAST CANCER DEVELOPMENT 
Breast cancer may occur whenever breast cells lose control in the mechanism that governs 
proliferation, differentiation, and apoptosis (Jones & Burris-III, 2000, p.1771). In breast cancer, 
the proliferation of tumour cells is much higher than apoptosis. The tumour cells’ growth will be 
under the influence of various hormones (i.e., estrogen and progesterone), oncogenes, and 
growth factors (Jones & Burris-III, 2000, p.1771-1772). In fact, numerous growth factors play a 
role in breast cancer cell development, including transforming growth factor alpha and beta 
(TGF-α and TGF-β), insulin-like growth factors I and II (IGF-I and IGF-II), platelet-derived 
growth factor (PDGF), and procathepsin D (52K protein) (Jones & Burris-III, 2000, p.1772). 
Furthermore, estrogen receptors (ER) are highly expressed in most breast cancer cells, so 
circulating estrogen will promote the growth of breast tumours. Bcl-2 oncogene and tumour 
suppress p53 gene, which regulates the cell apoptosis, show mutations in many breast cancer 
patients and promote cancer cell growth (Lindley & Michaud, 2005, p.2339). 
1.1.3.3. MOLECULAR BREAST CANCER SUBTYPE:  
 In the last two decades, our understanding of breast cancer biology has increased. According 
to this knowledge, we can categorize breast cancer into three sub-types: Luminal/ER positive, 
HER-2, and Basal (Atieh & Vahdat, 2008, p.310; Davies & Hiscov, 2011). Luminal/ER positive 
is further sub-divided into: luminal A, which is highly expressed with ER, and luminal B, which 
is characterized by moderate to low ER expression. HER-2 sub-types are highly expressed with 
human epidermal growth factor receptors-2 (HER-2).  Basal-like or triple negative sub-type is 
associated with the absence of receptor expression (i.e., ER-ve, PR-ve, and HER-2 -ve) (Davies 
& Hiscov, 2011). Understanding breast cancer sub-types in each patient is an important 
prognostic factor as it predicts the clinical outcome, progression, and survival (Atieh & Vahdat, 
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2008, p.312-313; Davies & Hiscov, 2011). In addition, it is a critical distinction determining the 
treatment decision by the clinical team (Davies & Hiscov, 2011). 
1.1.4. TREATMENT 
 Different types of therapy are available for the treatment of breast cancer. Some are currently 
applied and approved for clinical use and others are still in clinical trial. The medical team 
designs treatment based on the patient’s prognostic factors, such as the presence of lymphatic or 
vascular invasion, tumour size, hormonal receptors status (i.e. ER+, ER-, PR+, or PR-), 
proliferation index, the expression of HER-2, mutation of tumour suppresser p53 gene, growth 
factors levels, cathepsin D, and angiogenesis factors (Lindley & Michaud, 2005, p.2338-2340). 
The treatment options available are as follow: surgery, radiation, chemotherapies, endocrine 
therapies, and biological therapies (Figure 2). Surgery can include lumpectomy, or simple, or 
total mastectomy. The lumpectomy is usually followed with radiation therapies and is less 
invasive than a mastectomy (Lindley & Michaud, 2005, p.2341). However, mastectomy is a 
good option to ensure no recurrence of breast cancer (Lindley & Michaud, 2005, p.2341). 
Chemotherapies are mainly used in combination. The most common chemotherapies used in 
breast cancer are cyclophosphamide, doxorubicin, 5-flurouracil, docetaxel, paclitaxel, 
methotrexate, and vincristine (Lindley & Michaud, 2005, p.2355-2357). Endocrine therapies 
involve the use of anti-estrogen agents, like tamoxifen or aromatase inhibitors like letrozole 
(Lindley & Michaud, 2005, p.2350-2355). Biological therapies include the monoclonal 
antibodies (e.g.,trastuzumab) and tyrosine kinase inhibitors (e.g., lapatinib) (Lindley & Michaud, 
2005, p.2357-2358). Despite the improvement in the clinical outcome of the breast cancer patient 
through the use of these treatment options, the mortality and morbidity rate of breast cancer 
remains high. We need to find a new target to treat breast cancer, such as targeting the 
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sphingolipid signalling pathway that has been found to be involved in cell apoptosis and 
proliferation processes in both normal and cancer cells.  
 
 
           
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.Curruent breast cancer treatment options.  
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1.2. SPHINGOLIPID SIGNALLING PATHWAY 
1.2.1. INTRODUCTION 
The sphingolipid signalling pathway represents a group of intracellular and extracellular 
bioactive lipid molecules, including ceramide (Cer), ceramide-1-phosphate, sphingosine (Sph), 
and sphingosine-1-phosphate (S1P) (Hait et al., 2006; Segui et al., 2006). Studies have shown 
that sphingolipids play an important role in regulating cell growth and survival; additional 
physiological functions include cell motility, differentiation, stress response, protein synthesis, 
carbohydrate metabolism, angiogenesis, and immunity (Hait et al., 2006; Segui et al., 2006; 
Sabbadini, 2006). Any alteration on the sphingolipid signalling will result in the development of 
serious pathophysiological disorders, such as cancer, cardiovascular diseases, diabetes, asthma, 
and inflammatory and infectious diseases (Hait et al., 2006; Segui et al., 2006; Sabbadini, 2006) 
(Figure 3). Subsequent sections are focused on the role that sphingolipids play in breast cancer 
development, progression, and drug resistance development. 
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Figure 3. Diseases associated with alteration in the sphingolipid pathway.  Sphingolipids affect 
almost every organ in the human body and are associated with numerous pathophysiological 
disorders. 
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1.2.2. SPHINGOLIPID CHEMICAL STRUCTURE 
Sphingolipids are a class of lipids that are defined by their eighteen carbon amino-alcohol 
backbones (Gault, Obeid & Hannun, 2010). The modification of this basic structure will give rise 
to a wide family of sphingolipids (Gault, Obeid & Hannun, 2010). Sphingosine, 
phytosphingosine and dihydrosphingosine act as the precursors upon which more complex 
sphingolipids are formed by phosphorylation or acetylation (Gault, Obeid & Hannun, 2010).  
1.2.3. ROUTE OF SYNTHESIS  
Sphingolipids are generated by two routes: de novo biosynthesis and recycling of 
sphingomyelin (SM) (Figure 4). SM is one of the membrane phospholipids found in the plasma 
membrane, nucleus, endoplasmic reticulum (ERt), Golgi apparatus, and lysosome; however, 70- 
90% of SM is present mainly in the plasma membrane (Gault, Obeid & Hannun, 2010). The de 
novo biosynthesis occurs in the ERt, which contains the enzymes responsible for the biosynthesis 
of ceramide (Cer) (Gault, Obeid & Hannun, 2010). The cytosolic serine and palmitoyl-CoA 
molecules are condensed in the ERt by the action of three enzymes serine palmitoyltransferase, 
3-ketodihydrosphingosine reductase, and dihydroceramide synthase to give dihydroceramide, 
which then desaturates to give Cer, the first sphingolipid present in the cycle (Gault, Obeid & 
Hannun, 2010). The Cer generated by this route will travel from ERt to Golgi apparatus by 
CERT (ceramide transporter protein) where it converts to SM, glycosphingolipids, or Cer-1-
Phosphate (Gault, Obeid & Hannun, 2010). The recycling of the SM route occurs as a result of 
SM catabolism that will produce Cer, Sph, and S1P by the action of the following enzymes: 
SMase, ceramidase, and SK, respectively (Gault, Obeid & Hannun, 2010). S1P is the last 
sphingolipid in the cycle and it will reversibly undergo dephosphorylation via S1P-phosphatase 
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to form Sph, or it will undergo an irreversible cleavage via S1P-lyase to form hexadecenal and 
ethanolamine phosphate (Gault, Obeid & Hannun, 2010).  
 
Figure 4. Sphingolipid metabolism: The de novo biosynthesis pathway and the recycling of 
sphingomyelin. The first step begins in the endoplasmic reticulum were serine and palmitoyl-
CoA condense by the action of three enzymes to generate dihydroceramide that is desaturated to 
give rise to ceramide. The ceramide produced in the ERt will traffic to Golgi apparatus by CERT 
(ceramide trasporter protein) where it is further metabolised to sphingomyelin by shingomyeline 
synthase, glycosphingolipids, or phosphorylate by ceramide kinase to give ceramide-1-
phosphate. The recycling of sphingomyelin in the plasma membrane, lysosome or nucleus by 
sphingomyelinase enzyme will generate ceramide that is further degraded to sphingosine by the 
action of ceramidase. Sphingosine will be phosphorylated by sphingosine kinase to give 
sphingosine-1-phosphate, the last sphingolipid in this cycle that will undergo irreversible 
cleavage by the action of sphingosine-1-phosphate lyase to ethanolamine phosphate and 
hexadecenal or dephosphorylation by sphingosine-1-phosphate phosphatase to turn back to 
sphingosine. 
*(1, 2, and 3): serine palmitoyltransferase, 3-ketodihydrosphingosine reductase, and 
dihydroceramide synthases. 
- This figure is adapted from, (Gault, Obeid and Hannun, 2010). 
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1.2.4. SPHINGOLIPID AND CELL REGULATION 
The sphingolipid signalling pathway is important for cell viability. Studies in yeast culture 
have shown that cells cannot survive when they are unable to produce sphingomyelin (Cerantola 
et al., 2009) or if they have a defect in the de novo synthesis route (Sutterwala et al., 2007). In 
addition, evidence shows that the balance between Cer- Sph and S1P levels is critical to the cells; 
it determines the cell’s fate towards death or survival (Oskouian & Saba, 2010; Sabbadini, 2006). 
Many studies suggest that Cer and Sph are the death-promoting sphingolipids, and S1P is the 
growth-promoting sphingolipid (Oskouian & Saba, 2010; Sabbadini, 2006). When a cell 
undergoes apoptosis, it directs the sphingolipid signalling pathway towards Cer and Sph 
synthesis; in contrast, when it undergoes proliferation it will direct this pathway toward S1P 
synthesis (Oskouian & Saba, 2010; Sabbadini, 2006). Sphingolipids affect every aspect involved 
in cell regulation (Zheng et al., 2006).  
1.2.4.1. CELL APOPTOSIS PATHWAY 
Apoptosis, also called “cellular suicide”, is the programmed death of the cell. It is different 
from necrosis in that it occurs under a normal physiological condition (Makin, 2002). There are 
two pathways in which a cell undergoes apoptosis: the extrinsic route and the intrinsic route. The 
extrinsic pathway is mediated by the activation of the death receptors that are present in the cell 
surface (i.e. TNF-α and Fas receptors) (Makin, 2002). The stimulation of these receptors 
activates caspase-8, causing activation of downstream caspases and apoptosis (Makin, 2002). 
The intrinsic pathway is mediated through permeabilization of the outer mitochondrial 
membrane, which leads to the release of mitochondrial cytochrome c, the activation of caspase-9, 
and, as a result, apoptosis (Makin, 2002). This pathway is mediated via the activation of the pro-
apoptotic members of the Bcl-2 protein family, which are present in the mitochondrial surface. 
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These members include: Bcl-x(s), BAX, BAK, BAD, and BID (Makin, 2002). However, this 
route can be blocked by the activation of anti-apoptotic members of Bcl-2 protein family, such as 
Bcl-2 and Bcl-x (L) (Makin, 2002). Sphingolipids have been found to play a major role in 
regulating both apoptosis routes (Oskouian & Saba, 2010).While Cer will enhance apoptosis, 
S1P will protect the cell against apoptosis and will direct the cells towards proliferation and 
survival by the activation of sphingosine-1-phosphate receptor subtype 1 (S1PR1) and 
sphingosine-1-phosphate receptor subtype 3 (SIPR3). At the same time, S1P could also enhance 
apoptosis by unknown mechanisms (Oskouian & Saba, 2010).   
Cer exerts its apoptotic effect through the activation of the intrinsic and extrinsic apoptosis 
pathways (Oskouian & Saba, 2010) ( Figure 5). It activates the extrinsic pathway though 
stimulation of both death receptors (i.e., TNF-α and Fas) (Oskouian & Saba, 2010). Cer activates 
TNF-α receptor via regulating Bid. It directly binds to cathepsine D, which cleaves Bid, causing 
activation of TNF-α. Cer can also stimulate the Fas receptor through its biophysical properties. 
Cer aggregates into the surface membrane, allowing the membrane to undergo structural changes 
that causes the activation of Fas (Zheng et al., 2006; Oskouian & Saba, 2010). Cer affects the 
intrinsic pathway by regulating two members of Bcl-2 protein family: the pro-apoptotic protein 
Bax and the anti-apoptotic Bcl-2 protein (Oskouian & Saba, 2010). Cer can down-regulate Bcl-
x(L), stimulate Bcl-x(s), and activate Bax causing induction of apoptosis. 
Conversely, S1P may stimulate cell proliferation and inhibit cell apoptosis by activating a 
group of five cell surface receptors that are a family of G-protein-coupled receptors (i.e., S1PRs) 
(Oskouian & Saba, 2010). The activation of S1PRs, particularly, S1PR1 and S1PR3, blocks the 
apoptosis pathway by down-regulating Bax expression, inactivating Bad, inhibiting any change 
in the mitochondrial membrane potential, preventing cytochrome c release, and protecting 
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against Fas induced apoptosis (Oskouian & Saba, 2010) (Figure 5). Oddly, evidence suggests 
that S1P can induce apoptosis independent of S1PRs, and while the mechanism is still unclear, 
some researchers correlate S1P apoptotic effect to its intracellular action (Oskouian & Saba, 
2010). 
1.2.4.2. DEATH SIGNALLING 
Cer has an effect either directly or indirectly on different pathways that promote cell death 
(Signorelli & Ghidoni, 2005; Zheng et al., 2006) (Figure 6). It can induce the stress activating 
protein kinase (JNK), and phosphoprotein phosphatease 1 and 2A (PP1 and PP2A) and activate 
kinase suppressor of Ras (KSR) and the pro-apoptotic atypical protein kinase C (PKC) causing 
cell death (Signorelli & Ghidoni, 2005; Zheng et al., 2006). Contrarily, S1P will oppose Cer 
actions by suppressing JNK, leading to cell survival and growth; it can also increase the levels of 
pro-growth and angiogenesis factors such as EGF, PDGF, and VEGF (Oskouian & Saba, 2010).  
1.2.4.3. GROWTH AND SURVIVOR SIGNALLING 
Stimulation of the PI3K/AKT pathway will facilitate the cell cycle progression, inhibit cell 
apoptosis, suppress autophagy, and enhance nutritient uptake and cell growth and survival 
(Oskouian & Saba, 2010). Studies have found in many cancer patients the presence of a mutation 
in this pathway, which is usually correlated with tumour progression and treatment resistance 
(Oskouian & Saba, 2010). Cer acts as a down-regulator of the PI3K/AKT pathway causing 
inhibition of the cell proliferation and induction of autophagy (Oskouian & Saba, 2010). On the 
other hand, S1P acts as an up-regulator for the PI3K/AKT pathway causing stimulation of cell 
proliferation and increases cell survival; this effect requires the activation of S1PR1 and S1PR3 
(Oskouian & Saba, 2010). Surprisingly, S1P activation of S1PR2 blocks the PI3K/AKT 
signalling pathway. In addition, sphingolipids have been found to affect another survival 
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signalling pathway the ERK/MAPK pathway (Oskouian & Saba, 2010). S1P will activate this 
pathway, leading to cell survival and protection against cell death (Oskouian & Saba, 2010).   
1.2.4.4. CELL MOTILITY 
Cells rely on cellular movement to maintain some important biological processes, such as 
cellular development and response to infection and injury. Growth factors are important 
regulators of the cell movement mechanism. Generally, S1P can stimulate cell motility through 
the activation of S1PRs surface receptors, particularly S1PR1 and S1PR3 (Oskouian & Saba, 
2010; Pyne & Pyne, 2010). It has been found that EGF stimulates SK to increase the production 
of S1P, which will act on S1PR1 and S1PR3 to induce cell motility. Oddly, the activation of 
S1PR2 inhibits cell motility. As a result, the S1P effect on cell motility will be determined by the 
S1PRs sub-type predominantly expressed in certain tissues (Oskouian & Saba, 2010; Pyne & 
Pyne, 2010).   
1.2.4.5. CELL CYCLE PROGRESSION  
The cell cycle involves DNA replication and cell division and has four phases known as G1, 
S, G2 and M phase (Vermeulen, Van Bockstaele & Berneman, 2003). The cyclins and the cyclin 
dependent kinases (CDK) are the two key regulatory proteins of the cell cycle (Vermeulen, Van 
Bockstaele & Berneman, 2003). The G0 is known as the resting phase, in which the cell leaves 
the cycle and ceases replication (Vermeulen, Van Bockstaele & Berneman, 2003). The G1, S, 
and G2 phases are the interphase, during which cell growth takes place and DNA replication 
occurs (Vermeulen, Van Bockstaele & Berneman, 2003). The M phase is the mitotic phase, 
during which the cell splits itself into two daughter cells (Vermeulen, Van Bockstaele & 
Berneman, 2003). The CDKs are activated upon binding with cyclins and different CDK-cyclin 
complexes will affect different phases of the cell cycle (Vermeulen, Van Bockstaele & 
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Berneman, 2003). The most common cyclins include cyclin A, B, C, E, F, G, H, K, and T 
(Vermeulen, Van Bockstaele & Berneman, 2003). The CDKs which are particularly important in 
the cell cycle include CDK1, CDK2, CDK4, and CDK6 (Vermeulen, Van Bockstaele & 
Berneman, 2003). Cer may promote cell death through inhibition of the cell cycle progression 
(Oskouian & Saba, 2010; Lee, Bielawska & Obeid, 2000). Cer can cause G1 cell cycle arrest via 
regulation of CDK2-cyclin complex activity and induction of p21 expression that activates p53 
leading to inhibition of the DNA replication (Oskouian & Saba, 2010; Lee, Bielawska & Obeid, 
2000). In addition, Cer can inhibit telomerase expression and this will block cell growth because 
telomerase is a ribonucleoprotein enzyme complex that is required during the replication phase 
of the cell cycle and its inhibition will interrupt the cell growth (Oskouian & Saba, 2010). 
Therefore, Cer causes cell death through suppression of CDK2-cyclin complex activity and 
inhibition of telomerase enzyme.  
1.2.4.6. CELL AUTOPHAGY 
Autophagy is a catabolic pathway, which involves the degradation of unnecessary or 
dysfunctional cellular components by lysosomes (Janku, McConkey, Hong & Kurzrock, 2011). 
It is a tightly controlled process, which helps to maintain the balance between cell synthesis and 
degradation (Janku, McConkey, Hong & Kurzrock, 2011). In addition, autophagy is important in 
maintaining cellular homeostasis (Janku, McConkey, Hong & Kurzrock, 2011). Beclin-1 is one 
of the essential regulators of this process (Chen & Karantza-Wadsworth, 2009). When the cell is 
suffering from nutrition deprivation it induces the autophagy process. This facilitates the binding 
of beclin-1 to Bcl-2 pro-apoptotic members, such as BID, BAD, BAK, and BIM causing cell 
death (Chen & Karantza-Wadsworth, 2009). In addition, the growth factor signalling pathway, 
PI3K/Akt/mTOR, plays a major role in regulating the autophagy process (Chen & Karantza-
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Wadsworth, 2009). Stimulation of the PI3K/Akt/mTOR pathway negatively regulates cell 
autophagy process (Chen & Karantza-Wadsworth, 2009). Sphingolipids are also involved in 
regulating the autophagy process (Oskouian & Saba, 2010). Both Cer and S1P cause induction of 
the cell autophagy but by different mechanisms. Cer induces autophagy by up-regulating beclin-
1 and down-regulating the PI3K/AKT pathway, while S1P enhances autophagy independently of 
the PI3K/AKI pathway and, rather, exerts its effect by direct inhibition of mTOR (Oskouian & 
Saba, 2010). 
1.2.4.7. INFLAMMATION AND IMMUNITY 
 When cells get infected or injured the inflammatory process will be the first response of the 
immune system (Aggarwal & Gehlot, 2009). Inflammation is associated with redness and 
swelling of the injured or infective site (Aggarwal & Gehlot, 2009). The most common 
regulators of inflammation are the cytokines and eicosanoids. The main cytokines involved in the 
inflammation are the interleukins, chemokines, and interferons (Aggarwal & Gehlot, 2009). The 
eicosanoids include prostaglandin and leukotriene. The release of cytokines and eicosanoids 
promote the movement of leukocytes and cause vasodilatation of the blood vessel (Aggarwal & 
Gehlot, 2009). Growth factors and cytotoxic factors play a role in regulation of the inflammation 
response (Aggarwal & Gehlot, 2009). However, studies have found an association between 
inflammation and sphingolipids, particularly SK-S1P pathway. The SK activity increases in 
response to inflammatory mediators, such as TNF-α (Pyne & Pyne, 2010). In addition, S1P up-
regulates the expression of cyclooxygenase 2 (COX2) and stimulates the production of 
prostaglandin E2 (PGE2) (Pyne & Pyne, 2010). Moreover, stimulation of S1PR1 enhances 
immune cell function and plays an important role in controlling lymphocyte recirculation and 
 19 
 
trafficking (Hait et al, 2006). Thus, the SK-S1P signalling promotes carcinogenic inflammatory 
effect via generation of PGE2 and up-regulation of COX2 (Oskouian & Saba, 2010).   
To conclude, sphingolipid effects on the cells are complex. They are involved in every aspect 
that regulates cell function and development. Cer and S1P have opposite effects on cell fate; 
however, their effect on cell autophagy is similar. The S1P function on the cell is much more 
complex than the other sphingolipids; S1P has a wide range of effects on cell fate and migration 
(Oskouian & Saba, 2010).  
 
 
 
 
 
 
 
 
 
 
Figure 5. Ceramide and sphingosine-1-phosphate affect on the intrinsic and extrinsic apoptosis 
pathways. Ceramide will down-regulate the anti-apoptotic protein Bcl-x(L), enhance pro-
apoptotic proteins  Bcl-x(s) and Bax, stimulate cathepsin D that can activate the pro-apoptotic 
protein Bid leading to stimulation of TNF-α, and  ceramide can aggregate into the membrane 
causing activation of Fas receptors. In contrast, sphingosine-1-phosphate will down-regulate Bax 
and Bad protecting the cells against apoptosis.  
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Figure 6.  Ceramide stimuli and effect on the cell. Ceramide has diverse stimuli to enhance its 
production including: environmental stress, TNF, IL-1β, radiation, chemotherapies and 
chemopreventive agents. The production of ceramide will direct the cell toward death. Ceramide 
will enhance cell apoptosis by affecting both the intrinsic and the extrinsic pathway, it will arrest 
cell cycle at G0/G1, and will stimulate different death signals e.g. JNK, KSR, PP1, and PP2A. In 
addition, it will cause downregulation of PI3K/AKT pathway and will enhance auto-phagy. 
Note: (         ) means stimulation, and (        ) means inhibition.  
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1.2.5. SPHINGOLIPIDS AND DISEASES 
Any alteration in the sphingolipid signalling pathway is associated with the development of 
numerous diseases, such as cardiovascular disorders, atherosclerosis, respiratory disorders, 
diabetes, Alzheimer’s, inflammatory diseases, and cancer (Figure 3). For this reason, research in 
this area has gained high interest among scientists in the last decade. Each sphingolipid has a 
specific role in cells and regulates important physiological functions. The accumulation of Cer in 
the brain is associated with cerebral ischemia and stroke; in addition, studies suggest that Cer 
contributes in the development of Alzheimer’s disease (Stiban, Tidhar & Futerman, 2010). 
Moreover, the up-regulation of Cer via the de novo pathway is involved in lung alveolar cell 
apoptosis and contributes to the development of asthma and COPD (Stiban, Tidhar & Futerman, 
2010). In addition, the S1P level is elevated in broncholavage fluid of asthmatic patients and 
many studies suggest that S1P is involved in promoting allergic and inflammatory responses in 
COPD and asthma patients (Hait et al., 2006). In the last decade remarkable progress has been 
made to elucidate the involvement of sphingolipids in different disorders and the subsequent 
sections focus on sphingolipids’ role in cancer.  
1.2.6. SPHINGOLIPDS AND CANCER 
In cancer, studies have shown that sphingolipids and the enzymes that mediate their function 
and metabolism play a major role in the pathophysiology, progression, and treatment resistance 
of the disease (Signorelli & Ghidoni, 2005). Sphingolipids are also involved in chemotherapies 
and the radiation mechanism of action of cancer cells killing and are associated with 
development of cancer drug resistance. Moreover, sphingolipids regulate cancer metastasis and 
angiogenesis. Many drugs have been developed to target sphingolipids signalling pathways in 
cancer treatment.  
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1.2.6.1. EXPRESSION OF SPHINGOLIPIDS SIGNALLING IN CANCER 
Up-regulation of the Cer synthesis enzyme activity will induce apoptosis and its down-
regulation will increase tumour growth and survival (Oskouian & Saba, 2010; Signorelli & 
Ghidoni, 2005). In addition, the ceramidase has been found to be over-expressed in tumour cells 
and this enhances Cer degradation and protects tumour cells from apoptosis (Oskouian & Saba, 
2010). Another enzyme found to play a role in cancer is SK1, which is responsible for the 
phosphorylation of Sph to generate S1P. SK1 will promote proliferation and survival of tumour 
cells and its over-expression is correlated with resistance to medications (Pchejetski et al, 2005). 
SK1 was found to be over-expressed in solid tumours, including breast, kidney, ovary, prostate, 
and stomach cancers, and this suggests SK1 is involved in breast cancer development and 
progression (Nagahashi et al., 2012; Olivera et al., 1999). 
1.2.6.2. SPHINGOLIPIDIS AS MEDIATORS OF CHEMOTHERAPIES AND RADIATION 
Sphingolipids have been found to play role in the radiation, chemotherapy, and 
chemopreventive agent mechanism of action. Curcumin is a potent chemopreventive agent and 
studies reveal that it increases Cer levels in colon cancer cells through induction of the de novo 
pathway as part of its mechanism of protecting against cancer development (Moussavi, Assi, 
Gomez-Munoz & Salh, 2006). The NSAIDs are useful chemopreventive agents and their tumour 
suppression is related to the elevation of prostaglandin precursor arachidonic acid (AA) that in 
turn stimulates the conversion of SM to Cer (Chan, Morin, Vogelstein & Kinzler, 1998). 
Resveratrol is another chemopreventive agent, which exerts its effect by stimulation of the de 
novo synthesis and recycling of SM to increase the level of Cer (Signorlli & Ghidoni, 2005; 
Scarlatti et al., 2003). Docetaxel is anticancer drug commonly used in breast cancer and induces 
potent inhibition of SK1 expression and elevates the levels of Cer/S1P ratio as part of its 
 23 
 
mechanism of killing cancer cells (Pchejetski et al., 2005). Studies of doxorubicin effects in 
human head and neck squamous cell carcinoma have found that doxorubicin significantly 
elevates Cer levels (about 7-fold compared with the control) (Cuvillier et al., 2001; Sankala et 
al., 2007). Many anticancer medications, such as etoposide (Perry et al., 1999; Sawada et al., 
2000), Cisplatin (Min et al., 2007; Noda et al., 2001), imatinib (Bonhoure et al., 2008; Baran et 
al., 2007), and daunorubicin (Bose et al., 1995) increase the level of Cer as part of their 
mechanism of killing tumour cells via up-regulation of ceramide synthesis enzyme through 
stimulation of the de novo pathway, or via activation of SMase enzyme, which increases turnover 
of SM to Cer. Moreover, UVB radiation increases Cer levels as part of its mechanism of action 
(Bruno et al., 1998; Pena, Fuks & Kolesnick, 2000; Zeidan et al., 2008; Sakakura et al., 1996; 
Santana et al., 1996). 
1.2.6.3. SPHINGOLIPIDS AND CANCER METASTASIS AND ANGIOGENESIS 
As mentioned previously, S1P can regulate cell motility through activation of S1PRs cell 
surface receptors in both normal and cancer cells. Activation of S1PR1 and S1PR3 will enhance 
cell motility, while activation of S1PR2 will cause the opposite effect (Oskouian & Saba, 2010). 
Cancer cell migration increases a tumour’s metastatic potential; S1P will increase the risk of 
cancer metastasis development when the tumour cells highly express with S1PR1 and S1PR3 
(Oskouian & Saba, 2010). SK1 stimulation of EGF will trigger cell migration and metastasis 
(Huwiler & Zangemeister-Wittke, 2007). Moreover, S1P promotes endothelial growth and 
enhances blood vessel formation by interaction with VEGF signalling (Alvarez, Milstien & 
Spiegel, 2007). All of these data indicate that SK-S1P pathway may contribute in cancer cell 
metastasis, angiogenesis, invasiveness and progression. 
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1.2.6.4. SPHINGOLIPIDS AND CANCER DRUG RESISTANCE DEVELOPMENT 
Sphingolipid expression on cancer cells can be correlated with tumour cells sensitivity or 
resistance to treatment (Oskouian & Saba, 2010). Drug-resistant cells exhibit greater SK1 
activity, failure to accumulate Cer, and a higher S1P: Cer ratio (Oskouian & Saba, 2010). The 
expression of CERT, which is responsible of the transportation of Cer from ERt to the Golgi 
apparatus, is elevated in tumour-resistant cells (Oskouian & Saba, 2010). Over-expression of 
SK1 can enhance the expression of the P-glycoprotein (P-gp) transporter. The regulation of P-gp 
represents a major obstacle in cancer treatment (Huwiler & Zangemeister-Wittke, 2007). The up-
regulation of P-gp expression is correlated with chemotherapy failure because P-gp is an efflux 
transporter that will prevent anti-cancer drugs from entering the tumour cell to exert their effects 
(Huwiler & Zangemeister-Wittke, 2007).  
1.2.6.5. THE MOST COMMON APPROACH USED IN TARGETING SPHINGOLIPID IN 
CANCER THERAPY 
Based on the understanding of cancer biology and the sphingolipid signalling pathway 
involvement in cancer, a number of new cancer medications that are targeting the sphingolipid 
pathway have been developed (Huwiler & Zangemeister-Wittke, 2007). These medications 
promise to decrease the morbidity and mortality rates of women with breast cancer. Some of the 
strategies used to target sphingolipids include production of synthetic Cer analogs, inhibition of 
the enzymes that catalyze Cer catabolism, inhibition of SK1, production of S1PRs’s antagonist 
or agonist, and reactivation of genes such as S1P-lyase, SIP-phosphatase, SMase, or 
dihydroceramide desaturase (Oskouian & Saba, 2010). 
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 1.3. SPHINGOSINE-1-PHOSPHATE 
1.3.1. INTRODUCTION 
S1P is one of the bioactive sphingolipid metabolites that play an important role in many 
physiological and pathophysiological processes including regulation of cell growth, 
angiogenesis, and migration in both normal and tumour cells (Maceyke, Harikumar, Milstien & 
Spiegel, 2012). S1P has a complex effect on the cell, as it can enhance proliferation, survival, 
and migration in some cases, but also shows the opposite effects of inducing cell apoptosis and 
blocking cell movement. Consequently, S1P could play a major role in cancer treatment since it 
can act on both apoptosis and proliferation. Indeed, many studies found a direct link between 
S1P and many types of cancer including breast cancer (Signorelli & Ghidoni, 2005a). In the last 
several years, remarkable progress has been made to elucidate the function and role of S1P in 
cells. In the following sections, S1P’s function, enzymes regulating its level, and its role in breast 
cancer treatment and prevention will be explained.    
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1.3.2. THE ENZYMES THAT REGULATE SPHINGOSINE-1-PHOSPHATE 
LEVEL 
S1P levels are predominately controlled by three enzymes: sphingosine-1-phosphate 
phosphatase (S1P-Phosphatase), sphingosine kinase (SK), and sphingosine-1-phosphate lyase 
(S1P-lyase) (Oskouian & Saba, 2010) ( Figure 7). S1P is synthesized through phosphorylation of 
Sph, and this reaction is catalyzed by SK. Then S1P undergoes irreversible cleavage by the 
action of S1P-lyase to ethanolamine phosphate and hexadecenal, or it can be reversibly 
dephosphorylated by S1P-phosphatase back to Sph. 
 
 
 
 
 
Figure 7. The enzymes that regulate sphingosine-1-phosphate level. S1P is synthesized through 
the phosphorolyation of sphingosine by sphingosine kinase (SK) enzyme and will undergo 
irreversible cleavage by the action of sphingosine-1-phosphate lyase (S1P-lyase) to ethanolamine 
phosphate and hexadecenal or it can dephosphorylated by sphingosine-1-phosphate phosphatase 
( S1P-phosphatase) back to sphingosine.  
 
1.3.2.1. SPHINGOSINE KINASE 
SK has two isoforms and both catalyze the phosphorylation of Sph by the same mechanism 
(Oskouian & Saba, 2010). SK1 is stimulated by hormones, growth factors, cytokines, 
chemokines, and immunoglobulin, whereas SK2 has fewer stimuli than SK1, and include EGF, 
IgE, IL-1β, and TNF-α (Oskouian & Saba, 2010). SK1 promotes cell survival and growth by 
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decreasing the level of Cer, which it does by inhibiting Cer synthesis and increasing the 
production of intracellular S1P that will be released to the extracellular surface by ABCC1 or 
ABCG2, where it can bind to the cell surface S1PRs (Oskouian & Saba, 2010; Takabe et al., 
2010). Oddly, because it uniquely couples with S1P-phosphatase enzyme, SK2 counteracts the 
SK1 effect by inducing apoptosis through enhancing the Sph turnover in to Cer (Oskouian & 
Saba, 2010; Sabbadini, 2006). Studies have shown that SK1 and SK2 have different sub-cellular 
locations; SK1 is predominant in the cytosol and SK2 is present mainly in the nucleus and other 
sub-cellular compartments (Pyne & Pyne, 2010).   
1.3.2.2. SPHINGOSINE-1-PHOSPHATE PHOSPHATASE 
S1P can be dephosphorylated by the action of S1P specific phosphatases, known as S1P-
phosphatase 1 and 2 (Gault, Obeid & Hannun, 2010). These phosphatases are present in the 
endoplasmic reticulum and they catalyze S1P recycling to Sph (Gault, Obeid & Hannun, 2010). 
S1P-phosphatases play a role in regulating the reintroduction of Cer at the endoplasmic 
reticulum and affects S1P signalling (Gault, Obeid & Hannun, 2010). Over-expression of the 
S1P-phosphatase enzyme is associated with promoting the accumulation of Cer and reduction in 
the extracellular S1P release (Gault, Obeid & Hannun, 2010). Therefore, these phosphatases 
determine the metabolic fate of S1P and they affect the biological responses of S1P in the cell 
(Gault, Obeid & Hannun, 2010). 
1.3.2.3. SPHNGOSINE-1-PHOSPHATE LYASE 
S1P-lyase enzyme causes irreversible conversion of S1P to hexadecenal and 
phosphoethanolamine and this represents the final step in the sphingolipids pathway (Gault, 
Obeid & Hannun, 2010). S1P-lyase enzyme is mainly present in the endoplasmic reticulum 
(Gault, Obeid & Hannun, 2010). S1P-lyase has broad substrate specificity; it degrades many 
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sphingolipid phosphate bases including S1P, diydrosphingosine-1-phosphate, and 
phytosphingosine-1-phosphate (Gault, Obeid & Hannun, 2010). S1P-lyase role needs more 
clarification. Some studies have shown that S1P-lyase plays a major role in tissue development 
and is associated with many disorders, such as immunological diseases and cancer (Gault, Obeid 
& Hannun, 2010). 
1.3.3. SPHINGOSINE-1-PHOSPHATE DUAL EFFECT ON THE CELL 
Numerous data have reported that S1P has dual effects on the cell. S1P is a unique 
sphingolipids and has a complex role compared to other sphingolipids. Many observations 
revealed that S1P has intrinsic and extrinsic effects on the cell (Figure 8). The intracellular 
actions are usually associated with its apoptotic effect, while S1P extracellular actions are 
correlated with its proliferation effect and survival. The dual effects are mainly due to two 
factors: the sub-cellular location of S1P formation and S1PRs subtypes expression in certain cell. 
1.3.3.1. INTRACELLULAR ACTION 
S1P’s intracellular target is not well defined, but S1P acts as a second messenger regulating 
intracellular calcium mobilization (Hait et al., 2006). Studies suggest that S1P induces calcium 
release from the endoplasmic reticulum (Maceyke, Harikumar, Milstien & Spiegel, 2012). S1P 
produced in the nucleus by SK2 regulates histone acetylation and enhances their transcription 
(Maceyke, Harikumar, Milstien & Spiegel, 2012). In addition, the SK2 that is localized in the 
mitochondria produces mitochondrial S1P, which interacts with prohibitin 2 (PHB2) (Maceyke, 
Harikumar, Milstien & Spiegel, 2012). Therefore, mitochondrial S1P plays a role in 
mitochondrial respiration (Maceyke, Harikumar, Milstien & Spiegel, 2012). Although the 
intracellular effects of S1P are not well defined, many studies are correlating the apoptotic effect 
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of S1P to its intracellular action. More studies are needed to elucidate the intracellular role of 
S1P in the cell fate.   
1.3.3.2. EXTRACELLULAR ACTION 
S1P has the ability to activate cell surface S1PR1-5 family of G-protein-couple receptors; these 
receptors are formally called endothelial differentiation gene (EDG) receptors (Oskouian & 
Saba, 2010). The S1PRs have different expression levels in different tissues depending on the 
cell type. This explains the diversity of S1P functions (Table 1). S1PR1 and S1PR3 activation 
promote cell survival, migration, and angiogenesis (Oskouian & Saba, 2010). In contrast, 
stimulation of S1PR2 inhibits cell migration and increases vascular permeability (Oskouian & 
Saba, 2010). S1PR4 and S1PR5 have a narrow expression pattern compared to the other S1PRs, 
and their role and function is not clear (Oskouian & Saba, 2010).  
In summary, the effects of S1P are determined mainly by the S1PRs sub-types predominantly 
expressed in certain tissues and in differences in the sub-cellular location of SK1 and SK2 (Pyne 
& Pyne, 2010). S1P is present in the plasma at a higher level (0.2-0.9 µM) than at the 
intracellular level, but it has high protein binding affinity to serum albumin and lipoprotein 
(Hannun & Obeid, 2008; Ling et al., 2011). The effect of the SK-S1P signalling pathway on the 
cell is complex and depends on many factors, such as cell type, receptor expression, and sub-
cellular location of S1P formation (Pyne & Pyne, 2010). 
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Figure 8. The dual effect of sphingosine-1-phosphate (S1P) on cell fate. S1P exerts its 
proliferation effect through the stimulation of cell surface receptors (i.e. S1PRs) and its apoptosis 
effect through its intracellular action by unknown mechanism.  
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Table1. Summary of sphingosine-1-phosphate receptors (S1PRs) tissue distribution and function: 
S1PRs 
subtype 
Tissue 
Distribution 
Function 
SIPR1 Brain 
Lung 
Spleen 
Liver 
Heart  
Kidney  
Skeletal muscle 
Thymus 
Lymphoid 
1- Angiogenesis, vascular 
integrity 
2- Stimulate immune cell 
function, control lymphocyte 
recirculation 
3- Increase cell migration 
4- Enhance cell proliferation 
and survivor 
S1PR2 Brain 
Lung 
Spleen 
Liver 
Heart 
Kidney  
Skeletal muscle 
Thymus 
1- Inhibit cell migration 
2- Increase vascular 
permeability 
3- Promotes liver tissue 
remodelling in response to 
acute injury 
S1PR3 Brain 
Lung 
Spleen 
Liver 
Heart 
Kidney  
Skeletal muscle 
Thymus 
 Testis 
1- Increase cell migration 
2- Vascular integrity 
3- Regulate the Heart Rate 
4- Enhance cell proliferation 
and survivor  
S1PR4 Lymphoid tissue 
Leukocyte 
Bone Marrow 
Spleen 
Thymus 
unclear 
S1PR5 Oligodendrocyte 
Natural Killer 
Cells 
Brain 
Spleen 
Skin 
unclear 
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1.3.4. BREAST CANCER AND SPHINGOSINE-1-PHOSPHATE: 
A number of in vitro studies have been done to study the effect of S1P on different breast 
cancer cell lines and the results are remarkable. These studies found that S1P enhances the 
cytotoxicity of anticancer drugs (Ling et al., 2011), and inhibits motility and proliferation of 
breast cancer cells (Wang et al., 1999). 
The study conducted by Ling et al. found that exogenous administration of S1P can improve 
the docetaxel treatment potency in MCF7 breast cancer cells. The IC50 value of docetaxel alone 
was 3.4 µg/ml and its value when co-administrated with 1 µM S1P was 2.1 µg/ml. This means 
that S1P enhances the cytotoxicity of docetaxel against MCF7 breast cancer cells. In addition, in 
the same study Ling et al. found that S1P shows different apoptotic responses in MCF7 (breast 
cancer cells line) compared to MCF12A (normal breast cells line), and this suggests that its 
effect could be selective to cancer cells (Ling et al., 2011).  
Another study done by Wang et al. examined the involvement of S1PRs in the motility 
inhibition following exogenous administration of S1P on the following breast cancer cell line: 
MCF7, ZR75-1, MDA-MB 231, and BT 549. These researchers found that the S1P inhibition of 
the motility was independent of the receptor and was associated with the intracellular action of 
S1P. Following the administration of S1P, they measured its intracellular levels in the sample 
and found it much higher than the control; this suggests that S1P will inhibit cell motility by 
intracellular actions independent of S1PRs (Wang et al., 1999). 
Spiegel et al. found similar results to Wang et al.’s study regarding S1P’s effect on the breast 
cancer cells’ motility. Their study showed that S1P at ( 1- 10 µM ) concentration can inhibit the 
motility and proliferation of human breast cancer cell lines (MCF7 and MDA-MB 231), and that 
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S1P is more potent against more aggressive estrogen-independent breast cancer cells, MDA-MB 
231, compared to its effect on estrogen-dependent breast cancer cells, MCF7, which are less 
aggressive. This means that S1P could be a useful agent in suppressing the breast cancer 
metastasis in more aggressive breast cancer cells (Spiegel et al., 1994).  
From all of these studies, it is evident that S1P could be a good candidate for breast cancer 
treatment since it inhibits the cells metastasis and proliferation, induces apoptosis, and enhances 
the cytotoxicity of anti-cancer drugs like docetaxel. 
1.3.5. SPHINGOSINE-1-PHOSPHATE APOPTOTIC EFFECT: 
 Because many studies associate S1P with cell proliferation and survival, a number of drugs 
have been developed to inhibit S1P synthesis by blocking the SK enzyme. Other studies have 
found that S1P plays a major role in inducing apoptosis, showing that S1P has a dual effect on 
cell fate (Oskouian & Saba, 2010). This new finding has led to the possibility of future 
evaluations of the SK-S1P pathway and the conclusion that S1P generated from SK1 is 
associated with cell proliferation and needs activation of S1PRs, while S1P generated from SK2 
is correlated with the intracellular apoptotic effect (Oskouian & Saba, 2010). 
Davaille et al. examined the S1P proliferation effect on human hepatic myofibroblasts (hMF) 
and found that S1P exhibits potent inhibition of hMF proliferation: the IC50= 1 µM. In this study, 
they linked the anti-proliferation effect of S1P to its intracellular action and suggested the 
involvement of COX2. They found that S1P will induce COX2 expression as part of its 
mechanism of growth inhibition. They blocked the COX2 by dexamethasone and as a result the 
anti-proliferation effect of S1P was abolished. Also, this research group further found that S1P 
has a dual opposing effect on hMF. S1P can enhance the cell proliferation of hMF by activating 
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S1PRs at a nanomolar concentration and the apoptotic effect occurred at a micromolar 
concentration of S1P. In the same study, they found that S1P apoptotic effect is not related to its 
conversion to Sph or Cer. They examined the effects of Sph and Cer and found that S1P exerts 
its apoptotic effect via a caspase-dependent mechanism and that Sph stimulates apoptosis in a 
caspase-independent mechanism (Davaille et al., 2000; Davaille et al., 2002).  
Hung and Chuang found that S1P can induce apoptosis in human hepatoma cells (Hep3B) by 
increasing the expression of the Bax gene (Hung & Chuang, 1996). Moore et al. found that 
prolonged exposure to 10 µM S1P induces apoptosis in hippocampal neurons by increasing the 
level of intracellular Ca
2+
. S1P will enhance the release of Ca
2+
 from IP3-senestive stores. Also, 
they found that prolonged exposure to low levels of S1P (2 µM) did not cause any morphological 
change (Moore et al., 1999).  
All of these studies support the hypothesis that the S1P apoptotic effect is correlated with its 
intracellular action. Until now studies did not identify the S1P intracellular target that mediates 
its intracellular effects.  
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1.4. HYPOTHESIS 
We are proposing sphingosine-1-phosphate (S1P) as a target for breast cancer treatment and 
prevention: 
I. S1P induces apoptosis and necrosis in breast cancer cells and inhibits breast cancer cells 
proliferation.  
II. S1P enhances the cytotoxicity of anti-cancer drugs against human breast cancer cells in 
vitro and in vivo. 
III. S1P apoptosis effect is correlated with it intracellular action. 
 
1.5. OBJECTIVES 
 
I. Examine whether exogenous administration of S1P will selectivity induce apoptosis, 
necrosis and inhibit proliferation in breast cancer cell lines.  
II. Evaluate the therapeutic effect of S1P alone or in combination with anti-cancer drugs 
against breast cancer by using MCF7 xenograft mouse model (in vivo) and MDA-MB 231 
and MDA-MB 361 breast cancer cell line (in vitro).  
III. Study the  cell distribution of S1P following exogenous administration by using Raman 
imaging 
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2. MATERIALS AND METHODS: 
2.1. MATERIALS: 
Sphingosine-1-phospahte (S9666- 1 mg), docetaxel (01885- 5 mg), doxorubicin (D1515- 10 
mg) and cyclophosphamide (C0768- 1 gm) were purchased from Sigma-Aldrich (Oakville, ON, 
Canada). All the cells lines were purchased from American Type Culture Collection (ATCC) 
(Manassas, VA, USA): MDA-MB 231 cells (source: human breast adenocarcinoma, drive from 
pleural effusion), MDA-MB 361 cells (source: human breast adenocarcinoma, drive from 
metastatic brain), MCF7 cells (source: human breast adenocarcinoma, drive from pleural 
effusion) and the MCF12A cells (source: human mammary gland; breast). 
Penicillin/streptomycin solution was purchased from Sigma Life Science (Kansas city, MO, 
USA). Leibovitz’s L-15 media, Eagle’s Minimum Essential media, and 1:1 mixture of 
Dulbecco’s modified Eagle’s medium with ham’s F12 media and Fetal Bovine Serum (FBS) 
were purchased from ATCC. 0.25 % Trypsin EDTA, bovine insulin, human epidermal growth 
factor, cholera toxin, and hydrocortisone were purchased from Sigma Life Science. Horse serum 
was from ATCC. CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay, Caspase-
Glo® 3/7 Assay System, and CytoTox 96 ® Non-Radioactive Cytotoxicity Assay System were 
from Promega (Madison, WI, USA). Innovation Research of American (Sarasota, FL, USA) 
provided 0.72 mg 17-β Estradiol pellet with 60-day release. The Matrigel matrix came from BD 
Bioscience (Franklin lakes, NJ, USA). Balb/c female nude mice were obtained from Charles 
River Laboratories Canada, Inc (Senneville, QC, Canada). 
2.2. COMPOUNDS AND BUFFERS PREPARATION:   
Stock solutions were prepared for S1P dissolved in methanol at a 2.64 mM; docetaxel in 
ethanol at a 2 mg/mL; doxorubicin in water at a 1 mM; and cyclophosphamide in ethanol at a 
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100 mM. Additionally, 1x PBS buffer (pH 7.4) was prepared by dissolving the following 
chemicals in 800 mL distilled water: 8 g NaCl, 0.2 g KCl, 1.44 g of Na2HPO4, and 0.24 g of 
KH2PO4. The pH was adjusted to 7.4 by adding HCL and then volume was adjusted to 1L. The 
final PBS solution was sterilized by autoclaving. 4% paraformaldehyde was prepared by 
dissolving 4gm of paraformaldehyde powder in 100 mL of 1x PBS and the final solution was 
heated at   -    C water bath for one-two hours.  
2.3. CELL CULTURE: 
The cells were allowed to grow in monolayer (75 cm
2
 or 150 cm
2
 tissue culture flasks) and 
were cultured according to ATCC instructions (Table 2). The complete growth media for each 
cell line was supplemented with 1% penicillin/streptomycin solution. For MDA-MB 231 cells, I 
used Leibovitz’s L-15 media and supplemented it with 10% FBS; for MDA-MB 361 cells, I 
supplemented Leibovitz’s L-15 media with 20% FBS; for MCF7 cells and added 10% FBS and 
0.01 mg/ml bovine insulin to Eagle’s Minimum Essential medium; and for MCF12A cells, I used 
1:1 mixture of Dulbecco’s modified Eagle’s medium and ham’s F12 medium and I supplemented 
it with 20 ng/ml human epidermal growth factor, 100 ng/ml cholera toxin, 0.01 mg/ml bovine 
insulin, 500 ng/ml hydrocortisone, and 95% horse serum. The MDA-MB 231 and MDA-MB 361 
cells were incubated in a humidified cell culture incubator at     C, without CO2, while the 
MCF7 and MCF12A cells were incubated in the same condition but with 5% CO2. The media for 
all cultured cells was changed every two to three days. The cells were sub-cultured when they 
reached more than 80% confluency by using 0.25% trypsin EDTA 1X solution.   
2.4. CELL PROLIFERATION ASSAY: 
96-well tissue culture plates were seeded with MDA-MB 231 cells at a density of 7000 cells/ 
well, while the MDA-MB 361 cells were seeded at 10,000 cells/well. When the cells reached 60-
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70% confluency, they were treated with S1P (concentration range: 0.125- 8 µM) or methanol, 
and then incubated in     C, without CO2 for 18- 19 hours. After that, I performed the assay by 
using the CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay kit, following the 
manufacturer’s protocol. In the final step, I used a BioteK plate reader to measure the absorbance 
at 490 nm. This assay is a colorimetric method used to determine the number of living cells by 
measuring the quantity of Formazen. The Formazen is formed as a result of the conversion of 
MTS (i.e. 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium)), which is found in the assay solution. This conversion is catalysed by the 
dehydrogenase enzyme, which is usually found in metabolically active cells.  The data were 
plotted as % increase of cell proliferation compared to the control vs. S1P concentration and data 
was analyzed using GraphPad Prism software. For the time response assay, I did the same 
previous step but treated cells with 1, 10 µM S1P or methanol one time. Proliferation was 
measured at different time points (at 0, 6, 12, 24, 48, and 72 hours) and the final data were 
plotted as % increase of cell proliferation vs. time in hours.  
2.5. APOPTOSIS ASSAY: 
A total of 7000 MDA-MB 231 cells/well, 10,000 MDA-MB 361 cells/well, or 5000 of 
MCF12A cells/well were seeded in a white 96-well tissue culture plate. When the cells reached 
60- 70% confluency, they were treated with S1P (concentration range: 0.15625- 40 µM) or 
methanol; the treated cells were incubated at     C, humidified, without CO2 for 48 hours for 
MDA-MB 231 cells and 18 hours for MDA-MB 361 cells, while the MCF12A was treated for 24 
hours at     C, humidified, in 5% CO2. After that, I performed the apoptosis assay by using 
Caspase-Glo®  /  Assay System kit, following the manufacturer’s protocol. Later I used a 
BioteK plate reader to measure the luminescence that represented the caspase3/7 activity. This 
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assay is a homogenous luminescent assay, which measures the caspase 3/7 activity. The assay 
solution contains proluminescent caspase-3/7 DEVD- aminoluciferin substrate and proprietary 
thermostable luciferase. The presence of caspase 3/7 in the cell culture will cleave the substrate 
and free the aminoluciferin. The free aminoluciferin will be consumed by the luciferase enzyme 
to give a glow luminescence. For the calculation, I used the cells treated with solvent (i.e., 
methanol) without S1P as a control. Data were plotted as % increase of cells apoptosis compared 
to control vs. S1P concentration and I used GraphPad Prism software for my data analysis; to 
calculate the IC50 values I used the nonlinear regression analysis, log [agonist] vs. response 
equation.  
2.6. CYTOTOXICITY STUDIES: 
For this study, 96-well plates were seeded with 7000 MDA-MB 231 cells/well, 10,000 MDA-
MB 361 cells/well, or 5000 MCF12A cells/well. When the cells reached 60- 70% confluency, 
they were treated with S1P at concentration range of 0.15625- 40 µM to determine the 
cytotoxicity effect of S1P on these cell lines. I performed another cytotoxicity study on MDA-
MB 231 and MDA-MB 361 cells. Here, I treated the cells with a different concentration of the 
anti-cancer drugs alone or in combination with 1 or 10 µM S1P as follow: docetaxel 
(concentration: 40- 0.625 µg/ml), doxorubicin (concentration: 20- 0.3125 µM), or 
cyclophosphamide (concentration: 2- 0.0325 mM). After that, I incubated the treated cells for 18- 
19 hours for MDA-MB 231 and MDA-MB 361 cells, and 24 hours for MCF12A. In the next 
step, I performed the cytotoxicity assay by using CytoTox 96 ® Non-Radioactive Cytotoxicity 
Assay kit. In the end, I used a Biotek plate reader and I quantitatively measured lactate 
dehydrogenase (LDH), which is a cytosolic enzyme released upon cell lysis, by recording the 
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absorbance at 490 nm. The background absorbance was corrected by including a negative control 
and I determined the % cell death by using the following formula:  
% Cytotoxicity= 
                 
                                                    
 x 100 
The data were plotted as % cytotoxicity vs. S1P concentration for the first assay and vs. each 
anti-cancer drug concentration for the second assay; I used GraphPad Prism software to evaluate 
the data and I calculated the IC50 values by using the nonlinear regression analysis, log [agonist] 
vs response equation. To compare between the effects of the anti-cancer drugs alone or in 
combination with S1P I performed a t-test. For the time response assay, I treated the MDA-MB 
231 and MDA-MB 361 with 1, 10 µM S1P or methanol, one time treatment and I used the same 
previous steps and % cytotoxicity was measured at different time points (at 0, 6, 12, 24, 48, and 
72 hours). 
2.7. RAMAN IMAGING: 
The MCF7 cells were seeded at a density of 50,000 cells/well in a 45-well plates that 
contained a gold plate. I allowed the cells to grow on the gold plate for 24 hours, and then I 
treated the cells with 10 µM S1P for 12 hours. After that, I removed the media and washed the 
gold plate twice with1xPBS for both the control and the treated sample. Then I placed the gold 
plate in a Petri dish containing 2 ml 1xPBS, and I used the Raman spectrophotometer to detect 
the spectrum of the control and treated cells. When I found the S1P signal I did the mapping at 
the higher peak of S1P intensity signal, i.e. 1300 Raman shift/ cm
-1
, see Figure 20. Also, I 
measured the pure S1P powder extended and static spectrum and compared it with the 
experiment spectrum; although the sample signal is weak, it fit with the pure S1P signal.  
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2.8. ANIMAL STUDIES: 
This work was approved by the University of Saskatchewan’s Animal Research Ethics Board 
and adhered to the Canadian Council on Animal Care guidelines for humane animal use. Thirty 
4- 6 week old Balb/c female nude mice were housed in ventilated cages under sterile conditions, 
and sterile food and water were provided to them ad libitum. I used MCF7 cell line passage no. 
151 to develop the xenograft nude mice model. When the cells reached 70- 80% confluency, I 
injected 2- 5 x 10
6 
of MCF7 cells suspended in 1:1 of (1xPBS and Matrigel matrix) 
subcutaneously in the mammary fat pad of the nude mice by using a 1 cc syringe and a 27-guage 
needle. We implanted 0.72 mg of the 17-β Estradiol   -day release pellet beneath the lateral side 
of each mouse’s neck between the ear and the shoulder one day before the injection of the cells 
and this surgery was done while the mice are under isoflurane anesthesia. We implant the 
estrogen because MCF7 cells are estrogen-dependent breast cancer cells and estrogen facilitates 
its growth. The mice were monitored every three days during the tumour induction period. I 
started the treatment after 38 days post-cell injection. The tumour length and width was 
measured by using a digital calliper and the following formula was applied to calculate the 
tumour volume: V= 
 
 
 (width x length) 
3/2
. Only 14 mice developed the tumour which means that 
the tumour induction success rate is consistent with the literature which is usually (40- 60%). I 
assigned the 14 mice in to four different groups as follows: the first group was the control group 
(n= 2) treated with the 1xPBS only; the second group (n= 4) was treated with 1 µM S1P; the 
third group (n=4) was treated with 6 µg Docetaxel; and the fourth group (n=4) was treated with a 
combination of 1 µM S1P and 6 µg Docetaxel. I grouped the nude mice according to their weight 
and the weight difference in each group is less than 1 gram. All agents were given as intra 
tumoural injections with a total volume of 100 µL by using 27-gauge needles. Injections were 
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given every other day for 21 days (i.e., 10 doses were given). Tumour diameters, weight, and the 
life-span of the control and treated mice were recorded daily during the experiment.   
2.9. IMMUNOHISTOCHEMISTRY STUDIES: 
At the end of the animal experiment, all remaining mice were sacrificed and hearts, livers, 
kidneys and tumours were harvested. The collected tissues were embedded at 10x their volume 
in 4% paraformaldehyde for fixation and stored in the refrigerator for 72 hours. All tissues were 
washed with 70% ethanol before processing. The following day, I blocked the tissue in wax and I 
started sectioning the wax blocks in to 5 mm slices. Then I stained the slices with haematoxylin 
and eosin.  
2.10. STATISTICAL ANALYSIS: 
 I used GraphPad Prism software for my data analysis. The mean ± SD for each assay was 
calculated from three independent experiments. To calculate the IC50 values I used the nonlinear 
regression analysis, log [agonist] vs. response equation. To compare between the effects of the 
anti-cancer drugs alone or in combination with S1P I performed a t-test. In the animal study I 
performed a One-Way ANOVA followed by Tukey’s and Bonferroni’s multiple comparison 
tests to compare between the four groups.     
 
 
 
 
 
 
  
 
 
Table 2. Cell culture information summary: 
 
AC: Adenocarcinoma, Cauc: Caucasian, ER: Estrogen Receptors, PR: Progesterone Receptors, HER2: Human Epidermal Growth 
Factor Receptor 2, TP53: Tumour Protein 53, L-15: Leibovitz’s L-15 medium, MEM: Eagle’s Minimum Essential medium, 
DMEM/F12:  Dulbecco’s modified Eagle’s medium and Ham’s F12 medium, FBS: Fetal Bovine Serum.
Cell 
line 
Ethnic Gender Age 
(years 
Old) 
Gene 
Cluster 
Tumour 
Type 
Receptor Expression Source Passa
ge no. 
Culture Media Incubation 
conditions 
ER PR HER2 TP53 
MDA-
MB 
231 
Cauc. ♀ 51 Basal AC _ _ _ + Pleural 
effusion 
31 L-15, 10% FBS     C,  
No CO2 
MDA-
MB 
361 
Cauc. ♀ 40 Luminal AC + _ + _ Brain 33 L-15, 20 % FBS     C,  
No CO2 
MCF7 Cauc. ♀ 69 Luminal AC + + _ +/_ Pleural 
effusion 
149 MEM, 10% 
FBS 
    C,  
5%CO2 
MCF1
2A 
Cauc. ♀ 60 Basal F _ _  + Pleural 
effusion 
9 DMEM/F12*     C, 
5%CO2 
4
3
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3. RESULTS 
3.1. CELL PROLIFERATION ASSAY:  
 As shown in Figure 9, S1P produced a bell-shaped dose response curve on human breast 
cancer cell lines MDA-MB 361 and MDA-MB 231. Maximal proliferation was achieved at 1 µM 
and 2 µM in MDA-MB 361 and MDA-MB 231 cells, respectively. S1P caused a stimulatory 
response at a concentration lower than 2 µM and an inhibitory response at a higher concentration 
in MDA-MB 231 cells. In MDA-MB 361 cells, S1P caused a dramatic inhibition of cell 
proliferation at a concentration higher than 4 µM. In the time response study (Figure 10) 
prolonged exposure to high concentrations of S1P (i.e. 10 µM) significantly inhibited cell 
proliferation at a higher rate compared to lower concentrations (i.e. 1 µM) in both cell lines. 
Also, we observed that S1P was more effective against aggressive breast cancer cells (i.e. MDA-
MB 231 cells, ER-ve/ HER-2 -ve) compared to less aggressive cell line (i.e. MDA-MB 361 cells, 
ER +ve/ HER-2 +ve) as shown in Figure 10. Exposure of these breast cancer cells with 10 µM 
S1P for 72 hours inhibited the proliferation in both cell lines. However, in the MDA-MB 231 
cells the percent inhibition of proliferation was equal to 21%, while in MDA-MB 361 cells the 
percent inhibition was equal to 4%.  
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Figure 9. Percent increase of cellular proliferation (mean ± SD) compared to control of human 
breast cancer MDA-MB 231 cells (panel a) and MDA-MB 361 cells (panel b) following 18-19 
hr treatment with different concentrations of S1P. Cells treated with the complete growth media 
and the solvent was used as a control. The mean ± SD was calculated from three independent 
experiments.     
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Figure 10. Percent increase of cellular proliferation (mean ± SD) compared to control of human 
breast cancer MDA-MB 231 cells (panel a) and MDA-MB 361 cells (panel b). The cells were 
treated with 1, 10 µM S1P or methanol and cellular proliferation was measured at different time 
points (at 0, 6, 12, 24, 48, and 72 hr). Cells treated with the complete growth media and the 
solvent was used as a control. The mean ± SD was calculated from three independent 
experiments.   
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3.2. CELL APOPTOSIS ASSAY: 
The S1P IC50 ±SD in MDA-MB 231 breast cancer cells was 1.5 ±0.3 µM and in normal 
mammary epithelial MCF12A cells was 10.1± 5.0 µM as shown in Table 3 and Figure 11. This 
suggests greater apoptosis to cancer cells lines. As well, figure 11 (panel b) shows that S1P 
produced a bell-shaped dose response curve in MDA-MB 361 cells, with the maximal cell 
apoptosis at 0.3 µM.  
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Figure 11. Percent increase of apoptosis (mean ± SD) compared to control of human breast 
cancer cells , MDA-MB 231 cells (panel a) and MDA-MB 361 cells (panel b), and normal breast 
cells MCF12A (panel c), following treatment with different concentration of S1P for 48 hr (a), 
18 hr (b) or 24 hr (c). Cells treated with complete growth media and the solvent were used as a 
control. The IC50±SD was calculated from three independent experiments, see Table 3.  
 
Table 3. Summary of the sphingosine-1-phosphate half maximum inhibitory concentration 
results from the apoptosis and cytotoxicity studies:  
 
Cell Line IC50 ± SD * 
Apoptosis Cytotoxicity 
MDA-MB 231 cells 1.5 ± 0.3 8.5 ± 4.1 
MDA-MB 361 cells _ 14 ± 1.2 
MCF 12 A 10.1 ± 5 13.2 ± 5.6 
 
*IC50 shown for S1P is in µM. The cytotoxicity was determined by using Cytotox kit from 
Promega and apoptosis was determined by Caspase 3/7 kit as described in materials and 
methods section. The IC50 was calculated by using GraphPad Prism software and mean ± SD 
of three independent experiments was used.   
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3.3. CYTOTOXICITY STUDIES: 
S1P caused cytotoxicity in MDA-MB 231 cells at a lower concentration compared to MDA-
MB 361 and MCF12A cells, suggesting that S1P is more effective against MDA-MB 231 cells 
compared to MDA-MB 361 cells and that S1P can selectively kill MDA-MB 231 cells without 
harming normal breast cells as shown in Figure 12 and Table 3. In the time response study 
(Figure 13), prolonged exposure to higher concentrations of S1P caused higher cytotoxicity 
compared with lower concentrations and the effect was time dependent. S1P at 1 µM did not 
cause necrosis in normal and breast cancer cells. In Figures 14, 15, 16, and 17 S1P significantly 
enhanced the cytotoxicity of anti-cancer drugs docetaxel, doxorubicin and cyclophosphamide. In 
MDA-MB 231 cells, 1 and 10 µM of S1P enhanced the activity of docetaxel, doxorubicin, and 
cyclophosphamide significantly the p-value <0.05. In MDA-MB 361 cells S1P enhanced the 
cytotoxicity of chemotherapies only at 10 µM, which is consistent with previous results where 
S1P was shown to be more effective against MDA-MB 231 cells compared with MDA-MB 361 
cells. In Table 4 summarizes the IC50±SD values of anticancer drugs alone and in combination 
with S1P at an apoptosis dose (i.e., 1 µM) and necrosis dose (i.e., 10 µM). The data demonstrates 
the IC50 of anticancer drugs decreased significantly when co-administrated with 10 µM S1P 
compared with 1 µM S1P in both cell lines as shown in Figure 18 and 19. 
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Figure 12. Percent cytotoxicity (mean ± SD) compared to control of human breast cancer cells , 
MDA-MB 231 cells (panel a) and MDA-MB 361 cells (panel b), and normal breast cells 
MCF12A (panel c), following treatment with different concentrations of S1P for 48 hr (a), 18 hr 
(b) or 24 hr (c), respectively. Cells treated with complete growth media and the solvent were 
used as a control. The IC50±SD was calculated from three independent experiments, see Table 3.  
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Figure 13. Percent cytotoxicity (mean ± SD) compared to control of human breast cancer MDA-
MB 231 cells (panel a) and MDA-MB 361 cells (panel b). The cells were treated with 1, 10 µM 
S1P or methanol and the LDH release was measured at different time points (at 0, 6, 12, 24, 48, 
and 72 hr). Cells treated with the complete growth media and the solvent was used as a control. 
The mean ± SD was calculated from three independent experiments.    
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Figure 14. Percent cytotoxicity (mean ± SD) of the anticancer drugs against human breast cancer 
MDA-MB 231 cells alone (     ) or in combination with 1 µM S1P (     ), docetaxel (panel a), 
doxorubicin (panel b), and cyclophosphamide (panel c). The cytotoxicity was measured 18 hours 
after the treatment. Cells treated with the complete growth media and the solvent were used as 
the control. The mean ± SD was calculated from three independent experiments.   
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Figure 15. Percent cytotoxicity (mean ± SD) of the anticancer drugs against human breast cancer 
MDA-MB 231 cells alone (     ) or in combination with 10 µM S1P (     ), docetaxel (panel a), 
doxorubicin (panel b), and cyclophosphamide (panel c). The cytotoxicity was measured 18 hours 
after the treatment. Cells treated with the complete growth media and the solvent were used as 
the control. The mean ± SD was calculated from three independent experiments.   
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Figure 16. Percent cytotoxicity (mean ± SD) of the anticancer drugs against human breast cancer 
MDA-MB 361cells alone (     ) or in combination with 1 µM S1P (     ), docetaxel (panel a), 
doxorubicin (panel b), and cyclophosphamide (panel c). The cytotoxicity was measured 18 hours 
after the treatment. Cells treated with the complete growth media and the solvent were used as 
the control. The mean ± SD was calculated from three independent experiments.   
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Figure 17. Percent cytotoxicity (mean ± SD) of the anticancer drugs against human breast cancer 
MDA-MB 361 cells alone (     ) or in combination with 10 µM S1P (     ), docetaxel (panel a), 
doxorubicin (panel b), and cyclophosphamide (panel c). The cytotoxicity was measured 18 hours 
after the treatment. Cells treated with the complete growth media and the solvent were used as 
the control. The mean ± SD was calculated from three independent experiments.   
a. 
b. 
c. 
p-value < 0.0001 
p-value = 0.0589 
p-value < 0.0001 
%
 C
y
to
to
x
ic
it
y
 o
f 
M
D
A
-M
B
 3
6
1
 c
el
ls
 
%
 C
y
to
to
x
ic
it
y
 o
f 
M
D
A
-M
B
 3
6
1
 c
el
ls
 
%
 C
y
to
to
x
ic
it
y
 o
f 
M
D
A
-M
B
 3
6
1
 c
el
ls
 
 56 
 
 
 
 
 
 
 
Table 4. Anticancer drugs IC50 ± SD values alone and with apoptotic and necrotic doses of 
sphingosine-1-phosphate.  
 
 
*IC50 shown for: Docetaxel is in µg/ml, Doxorubicin is in µM, and Cyclophosphamide is in mM 
The cytotoxicity was determined by using Cytotox kit from Promega as described in materials 
and methods section. The IC50 was calculated by using GraphPad Prism software and mean ± SD 
of three independent experiments was used.  
 
 
 
 
 
 
 
Drug IC50 ± SD* 
MDA-MB 231 cells MDA-MB 361 cells 
Docetaxel alone 30.2 ± 34.1 17.8 ± 18.3 
    + 1 µM S1P 1.2 ± 1.1 60.5 ± 63.1 
    + 10 µM S1P 
 
0.01 ± 0.01 0.3 ± 0.4 
Doxorubicin alone 9 ± 16.8 24.5 ± 33.9 
    + 1 µM S1P 1.3 ± 1.1 10.1 ± 8.8 
    +10 µM S1P 
 
1.506000e+032 ± 0.00 92 ± 91 
Cyclophosphamide alone 0.3 ± 0.4 1 ± 1.4 
     + 1 µM S1P 0.04 ± 0.03 0.3 ± 0.4 
     +10 µM S1P 0.2 ± 0.3 0.02 ± 0.01 
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Figure 18. The IC50 (mean ± SD) of anticancer drugs against MDA-MB 231 breast cancer cells 
alone or in combination with 1 µM S1P, docetaxel (panel a), doxorubicin (panel b), and 
cyclophosphamide (panel c). The cytotoxicity was determined by using Cytotox kit from 
Promega as we describe in materials and methods. The IC50 was calculated by using GraphPad 
Prism software and mean ± SD of three independent experiments was used.  
a. 
b. 
c. 
 58 
 
Do
ce
ta
xe
l a
lo
ne
M
 S
1P

Do
ce
ta
xe
l w
ith
 1
0
50
100
150
IC
50
 v
al
ue
 (
g/
m
l)
 
Do
xo
ru
bi
ci
n 
al
on
e
M
 S
1P

Do
xo
ru
bi
ci
n 
wi
th
 1
0
20
40
60
80
IC
50
 v
al
ue
 (
M
)
 
C
yc
lo
ph
os
ph
am
id
e 
al
on
e
M
 S
1P

C
yc
lo
ph
os
ph
am
id
e 
w
ith
 1
0
1
2
3
IC
5
0
 v
al
ue
 (
m
M
)
 
Figure 19. The IC50 (mean ± SD) of anticancer drugs against MDA-MB 361 breast cancer cells 
alone or in combination with 1 µM S1P, docetaxel (panel a), doxorubicin (panel b), and 
cyclophosphamide (panel c). The cytotoxicity was determined by using Cytotox kit from 
Promega as we describe in materials and methods. The IC50 was calculated by using GraphPad 
Prism software and mean ± SD of three independent experiments was used. 
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3.4. RAMAN IMAGING: 
The S1P intensity was measured at point 1300 Raman shift/ cm
-1
 which is the strongest peak 
represent S1P. Figure 20 (panel a) indicates the presence of S1P inside the cells following 
exogenous administration.  
 
 
 
 
 
 
Figure 20. Raman Imaging data following the treatment of MCF7 cells with 10 µM S1P for 12 
hr. Picture of the cells under the microscope (panel b), the confocal Raman image of the cells 
(panel a). The Extended spectrum of pure S1P [red line], control [black line] and experiment 
[blue line] (panel c). The static spectrum of the experiment (panel d). 
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c. 
d. 
_ Pure S1P 
_ Control 
_ Sample 
Static Spectrum for 
MCF7 with 10 µM S1P   
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3.5. ANIMAL STUDY: 
During the experiment, I faced some difficulties in standardizing the tumour volume 
measurement method. Consequently, variations in the tumour volume were noted in the day -to- 
day measurement as shown in Figure 28 at the appendix page. In addition, the number of the 
nude mice that developed the tumour was low, the tumour induction success rate was around 
46%, and the initial tumour size of the mice in each group was different. All of this contributes to 
an increase of the error bar of the results. However, similar experiment was done by our 
collaborator in China and showed that there was a reduction in the tumor volume in S1P, 
docetaxel and combination group compared to the control as shown in Figure 21 & 26, and the 
reduction was significant.  
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Figure 21. Animal study results. The tumour volume (mm
3
) ± SD of the treated and control 
group during the 21 days of the experiment of MCF7 xenograft nude mice. In the last days of the 
treatment the tumour volume was different between the control group and the group who 
received the combination therapy. For the data analysis a One-Way ANOVA followed by 
Tukey’s and Bonferroni’s multiple comparison tests was performed by using GraphPad Prism.    
P-value<0.05 
S1P: yes 
Docetaxel: yes 
Combination: yes 
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3.6. IMMUNOHISTOCHEMISTRY STUDIES:  
Histopathology was conducted by Dr. Bruce K. Wobeser (Assistant Professor, Anatomic 
Pathology and Oncology at the University of Saskatchewan).   
3.6.1. HEART 
In Figure 22, there was no sign of cardiac damage in the control and treated nude mice 
groups. In all of the sections there were neither morphologic alterations present nor any evidence 
of inflammation or necrosis.  
3.6.2. LIVER: 
 In Figure 23, in the control and treated group, the liver tissue architectures were within 
normal limits and small numbers of neutrophils were observed within sinusoids. The hepatocytes 
of all the liver sections have mild anisocytosis and anisokaryosis with occasional binucleate 
cells. However, these changes were within the expected variability of mouse hepatocytes. 
3.6.3. KIDNEY: 
In Figure 24, the kidney tissue of the control and treated group show no sign of lesions. The 
architectures were within normal limits. There was no evidence of inflammation or necrosis. 
However, the tissue of one of the mice treated with docetaxel show exceptional small area of 
renal papilla where a small area of granular purple material was present. In size and shape it was 
similar to bacteria and there was no inflammation that was associated with it so it is likely of no 
significance. 
3.6.4. TUMOUR 
In Figure 25, in some of the sections there was no defined tumour mass present. There was 
abundant lymphocytic inflammation and fibroplasias scattered throughout the superficial dermis. 
However, in some of the treated group sections a single aggregate of tumour cells was found and 
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scattered lymphocytes were present within the neoplastic cells. No large or confluent areas of 
necrosis were present.  Rare individual cells were shrunken and eosinophilic, which was 
consistent with apoptosis (Figure 25). 
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Figure 22. The immunohistochemistry of mouse heart tissue. Each slice is 5 mm in size and was 
stained with hematoxylin and eosin. No toxicity was associated with chronic in vivo exposure 
with intratumoural injections of sphingosine-1-phosphate. The microscope magnification view is 
40x.   
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Figure 23. The immunohistochemistry of mouse liver tissue. Each slice is 5 mm in size and was 
stained with hematoxylin and eosin. No toxicity was associated with chronic in vivo exposure 
with intratumoural injections of sphingosine-1-phosphate. The microscope magnification view is 
40x.   
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Figure 24. The immunohistochemistry of mouse kidney tissue. Each slice is 5 mm in size and 
was stained with hematoxylin and eosin. No toxicity was associated with chronic in vivo 
exposure with intratumoural injections of sphingosine-1-phosphate. The microscope 
magnification view is 40x.   
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Figure 25. The immunohistochemistry of mouse tumour tissue. Each slice is 5 mm in size and 
was stained with hematoxylin and eosin. The microscope magnification view is 40x.   
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4. DISCUSSION 
Natural biological compounds have been rich resources for medical applications in cancer 
treatment and prevention.  The need to improve the cytotoxicity of the current available 
anticancer drugs continues to be important. Today there are a number of natural biological 
substances found to have the ability to induce apoptosis in different types of human tumour cells, 
such as sphingosine-1-phosphate (S1P). Several studies have demonstrated that S1P is associated 
with cell proliferation and survival potential making anti-S1P a good candidate for cancer 
treatment strategy. However, recent studies suggest the involvement of S1P in cell apoptosis 
(Oskouian & Saba, 2010; Davaille et al., 2000; Davaille et al., 2002; Moore et al., 1999). The 
exact function and role of S1P in normal and cancer cells need more clarification and this is 
exactly the goal of this research. I found that S1P is very similar to the newly indentified 
cytokine-induced apoptosis inhibitor, CIAPIN1, which has dual effects on cells cultures (Li, Wu 
& Fan, 2010). In my research I have done a number of experiments to evaluate the in vitro and in 
vivo effects of S1P against breast cancer cells.    
4.1. SPHINGOSINE-1-PHOSPHATE IS MORE EFFECTIVE AGAINST AGGRESSIVE 
BREAST CANCER  
In my research I obtained similar results to those reported by Spiegel et al. regarding S1P’s 
effect on different types of breast cancer cells. S1P was more effective against aggressive breast 
cancer cells, such as MDA-MB 231 cells (Figure 9, 10, 11, 12 and 13). Aggressive breast cancer 
cells are usually associated with the absence of estrogen and/or human epidermal growth factor-2 
receptors (i.e., ER-ve and/or HER-2 -ve). They are usually more invasive and possess higher 
metastatic potential. Aggressive breast cancer cells do not respond to hormonal therapy. 
Treatment of these cells with anti-estrogen, such as tamoxifen, is not effective and it is hard to 
find appropriate treatments to control their growth (Koduru et al., 2009). If the cancer cell 
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additionally lacks HER-2 receptors the treatment with monoclonal antibodies, such as 
trastuzumab, will fail. In addition, patients with ER-positive tumors have a median survival of 40 
- 48 months, while patients with ER-negative have median survival of only 10 - 20 months 
(Koduru et al., 2009).   In Spiegel et al.’s research they studied the effect of S1P at ( 1 or 10 µM) 
on the motility and proliferation of human breast cancer cells lines, including MCF7 and MDA-
MB 231 cells. The MCF7 cells are ER-positive and HER-2 -ve, while the MDA-MB 231 cells 
are ER-negative and HER-2 -ve. Spiegel et al. found that S1P inhibited the motility and 
proliferation of both cell lines, but S1P effect was more potent against the MDA-MB 231 cells 
(Spiegel et al., 1994). In my research I examined the effect of S1P in other breast cancer cells 
including the MDA-MB 361 cells, which are ER-positive and HER-2 +ve, and compared its 
effects to the MDA-MB 231 cells. In the proliferation studies (Figure10) I found that treatment 
of these breast cancer cells with 10 µM S1P for 72 hr inhibited proliferation in both cell lines. 
However, in the MDA-MB 231 cells the percent inhibition of proliferation was 21%, whereas in 
the MDA-MB 361 cells the percent inhibition of proliferation was only 4%. Thus, the percent 
inhibition of proliferation was much higher in aggressive MDA-MB 231 cells. In my cytotoxicity 
studies, I have found that the IC50 in the MDA-MB 231 cells was 8.5 µM, while the IC50 in the 
MDA-MB 361 was 14 µM (Figure 12 and Table 3), suggesting S1P may kill the aggressive 
breast cancer cells at lower doses. Treatment of both cell lines with 10 µM S1P for 72 hr killed 
39% of MDA-MB 231 cells and only 10% of MDA-MB 361 cells (Figure 13). S1P gave 
consistent response in the MDA-MB 231 cells compared with the MDA-MB 361 cells (Figure 12 
and 13). In my present study, I found that S1P (at 1 and 10 µM) significantly enhanced the 
cytotoxicity of the chemotherapy drugs including docetaxel, cyclophosphamides, and 
doxorubicin against the MDA-MB 231 cells (Figure14 and 15). However, in the MDA-MB 361 
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cells only high concentration of S1P (i.e., 10 µM) enhanced the cytotoxicity of the chemotherapy 
drugs, while the low concentration of S1P (i.e., 1 µM) had no effect (Figure 16 and 17). From all 
of this, I conclude that S1P could be a useful agent in the treatment of aggressive and metastatic 
breast cancers, which are hard to treat by using current available treatment.  
4.2. DIFFERENT EFFECT OF SPHINGOSINE-1-PHOSPHATE ON BREAST CANCER 
CELLS COMPARED WITH NORMAL BREAST CELLS 
I have found that S1P induced apoptosis in the breast cancer cells at low concentrations 
without harming normal breast cells. The IC50 for apoptosis in the MDA-MB 231 breast cancer 
cells was 1.5 µM, whereas the IC50 in normal breast cells (i.e., MCF12A) was 10.1 µM (Figure 
11 and Table 3). From the cytotoxicity studies I found that S1P caused necrosis in the MDA-MB 
231cells with IC50 of 8.5 µM, and in normal MCF12A cells the IC50 was 13.2 (Figure 12 and 
Table 3). Thus, my results are consistent with Ling et al.’s research finding that S1P had 
different apoptosis response in MCF7 cells compared to MCF12A cells (Ling et al., 2011). They 
suggested that S1P could selectively induce apoptosis in the MCF7 cancer cells (Ling et al., 
2011). My results showed that S1P induced apoptosis in breast cancer cells at low doses without 
harming normal cells. A major problem in current breast cancer therapies, such as 
chemotherapies, is that they lack the selectivity to tumors cells. Chemotherapies harm both 
normal and cancer cells leading to many undesirable effects that worsen the patient clinical 
outcome and increase the treatment cost. Chemotherapies are associated with nausea, vomiting, 
anemia, and neutropenia; because they kill rapidly divide cells, such as hair follicles, bone 
marrow, and gastrointestinal. To find an agent that is selective toward breast cancer cells will 
add a remarkable progress in improving the patient clinical outcome and will reduce the patients’ 
suffering from the chemotherapies side effects. The S1P addition to breast cancer treatment may 
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reduce the breast cancer morbidity, improve the patient clinical outcome, and reduce the 
treatment cost.  
4.3. SPHINGOSINE-1-PHOSPHATE IN COMBINATION WITH ANTI-CANCER DRUGS  
In the present study, I found that S1P enhanced the effect of anti-cancer drugs, such as 
docetaxel, cyclophosphamide, and doxorubicin against ER+ve/HER-2 +ve and ER –ve/HER-2 -
ve breast cancer cells in vitro (Table 4 and Figure 14, 15, 17, 18 and 19). These anti-cancer drugs 
are the most commonly used in breast cancer treatment (Chu & Sartorelli, 2009, p.900). 
Docetaxel is an antimitotic agent, which blocks cell division by inhibition of microtubule 
formation (Chu & Sartorelli, 2009, p.893). Cyclophosphamide is a nitrogen mustard alkylating 
agent, which arrests cell division by blocking the G2 stage of the cell cycle (Chu & Sartorelli, 
2009, p.882-883). Doxorubicin is an anthracyclin antibiotic, which arrests cell replication by 
forming complex with DNA, and inhibition of topoisomerase II enzyme activity (Chu & 
Sartorelli, 2009, p.893-894). Although these drugs’ mechanisms of action vary, we found that 
S1P can enhance their effectiveness regardless of the exact mechanism. However, there were 
slight differences in the percentage increase of cytotoxicity induced by S1P among these drugs. 
Also, in my study, I found that the percent increase of cytotoxicity of the anticancer drug was 
depended on the S1P concentration. The higher the S1P concentration the higher the cytotoxic 
effect can be achieved (Figures 14, 15, 16 and17). Co-administration of the anti-cancer drugs 
with high S1P concentration enhanced the cytotoxicity significantly (p-value < 0.0001) 
compared with low S1P concentration in MDA-MB 231 cells (Figure 14 and 15). Whereas, in 
the MDA-MB 361 cells low concentration of S1P did not enhance the cytotoxicity of anticancer 
drug, just the high concentration of S1P triggered the effect of the anti-cancer drugs (Figure 16 
and 17). However, my findings are similar to the previous study conducted by Ling et al. that 
 71 
 
exogenous administration of S1P can improved the docetaxel treatment potency in MCF7 breast 
cancer cells. The IC50 of docetaxel alone was 3.4 µg/ ml and its value from coadministration with 
1 µM S1P was 2.1 µg/ ml (Ling et al., 2011). This means that S1P enhanced the cytotoxicity of 
docetaxel against MCF7 breast cancer cells. From my work, S1P was shown to enhance the 
cytotoxicity of anticancer drugs not only in MCF7 but in other type of breast cancer cells such as 
the MDA-MB 231 and MDA-MB 361 cells. Moreover, S1P can enhance the activity of diverse 
chemotherapy regardless of their mechanism of action. The S1P enhanced the cytotoxicity of 
anti-cancer drugs depending on two factors: the S1P concentration and the breast cancer type 
(i.e., ER+ve/ HER-2 +ve or ER-ve/ HER-2 –ve). 
I undertook the in vivo studies of S1P alone or in combination with docetaxel in the BALB-C 
nude mice. Because of my lack of animal study experiences, my research results are not 
conclusive. Unquestionably, I faced some difficulties during the experiments as I mentioned 
previously in the results section. However, a similar study conducted through our collaborator in 
China showed that 1 µM S1P enhanced the cytotoxicity of docetaxel against MCF7 cells in vivo 
(Figure 21 and 26). The same collaborative group found similar results with the MDA-MB 231 
xenograft nude mice model (Figure 27). However, these results indicated that MDA-MB-231 
cells were more sensitive to S1P in vivo compared to MCF7 cells.   
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Figure 26. The percent increase of the tumor volume ± SEM of MCF7 xenograft mice after 
administration of docetaxel alone or in combination with sphingosine-1-phosphate (S1P) (panel 
a). The tumour weight mean (gram) ± SEM of MCF7 xenograft mice after administration of 
docetaxel alone or in combination with S1P (panel b). The mice received intra-tumoral injection 
and tumor dimension was measured daily for 21 days. The mean of each point was calculated 
from six nude mice. 
a. 
b. 
P-value<0.05 
S1P: yes 
Docetaxel: yes 
Combination: yes 
 
P-value<0.05 
S1P: yes 
Docetaxel: yes 
Combination: yes 
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Figure 27. The tumour volume mean (mm
3
) ± SD of MDA-MB 231 xenograft mice after 
administration of docetaxel alone or in combination with sphingosine-1-phosphate (S1P) (panel 
a). The tumour weight mean (gram) ± SEM of MDA-MB 231 xenograft mice after 
administration of docetaxel alone or in combination with S1P (panel b). The mice received intra-
tumoral injection and tumor dimension was measured daily for 21 days. The mean of each point 
was calculated from six nude mice.  
a. 
b. 
P-value<0.05 
S1P: yes 
Docetaxel: yes 
Combination: yes 
 
P-value<0.05 
S1P: yes 
Docetaxel: yes 
Combination: yes 
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4.4. THE ANTI-PROLIFERATION EFFECT OF SPHINGOSINE-1-PHOSPHATE IS 
CORRELATED TO ITS INTRACELLULAR ACTION 
In the present research, I studied the S1P cell distribution in MCF7 cells following exogenous 
administration of high concentration of S1P (i.e., 10 µM) by using the Raman imaging mapping. 
The literature revealed that external S1P will promote cell proliferation by activating S1PRs. 
However, my research suggests that external S1P undergoes a plasma-cell translocation (i.e., it 
can transport from the extracellular compartment to the cell) and that high concentration of S1P 
has anti-proliferation effects on breast cancer cells. I based this hypothesis on the fact that S1PRs 
are saturated at higher concentration of S1P and are only activated at nanomolar concentration 
(Davaille et al., 2000; Davaille et al., 2002). S1P can transport from plasma to the cell by 
ABCC7 transporter (Riboni, Giussani & Viani, 2010). From the Raman mapping I found that 
S1P was present mainly inside the cells following exogenous administration and its anti-
proliferative effect was correlated to its intracellular action, Figure 20. This result is similar to 
previous studies including: (Wang et al, 1999), (Davaille et al, 2000; 2002), (Hung & Chuang, 
1996), and (Moore et al., 1999). Wang et al., examined the involvement of S1PRs in the motility 
inhibition they observed following exogenous administration of S1P on the following breast 
cancer cell line: MCF7, ZR75-1, MDA-MB 231, and BT 549. They found that the S1P inhibition 
of cellular motility was independent of the receptors and it was associated with the intracellular 
action of S1P. Following the administration of S1P they measured its intracellular levels and 
found it was much higher than the control and this suggested that S1P inhibited cell motility by 
intracellular actions independent of the S1PRs (Wang et al., 1999). Davaille et al. examined the 
S1P proliferative effect on human hepatic myofibroblasts (hMF) and they found that S1P 
exhibited potent inhibition of hMF proliferation (IC50= 1 µM).  In this study they linked the anti-
proliferative effect of S1P to its intracellular action and suggested the involvement of COX2. 
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Hung & Chuang found that S1P can induce apoptosis in human hepatoma cells (Hep3B) by 
increasing the expression of the Bax gene (Hung & Chuang, 1996). Moore et al. found that 
prolong exposure to 10 µM S1P induced apoptosis in hippocampal neurons by increasing the 
level of intracellular Ca
2+
 (Moore et al., 1999). All of these studies: (Wang et al, 1999), (Davaille 
et al, 2000; 2002), (Hung & Chuang, 1996), and (Moore et al., 1999) are consistent with our 
finding that the S1P anti-proliferative effect is associated with its intracellular action. However, 
we need to identify the S1P intracellular target that triggers its effect. More researches is needed 
to clarify S1P intracellular action.   
4.5. DUAL EFFECT OF S1P ON BREAST CANCER CELLS 
S1P has a dual effect on cell fate and migration. The basic function of S1P is still unclear. 
However, it was found that S1P concentrations determine its final effect. In my proliferation 
studies, I saw that S1P at low concentration enhanced cell proliferation but at higher 
concentration it exhibited an anti-proliferative effect (Figure 9). In those studies, I found that S1P 
exhibited its maximal proliferative effect at 1 µM and 2 µM in MDA-MB 361 and MDA-MB 
231 breast cancer cells, respectively. S1P caused a stimulatory response at concentration lower 
than 2 µM and inhibitory response at a higher concentration in MDA-MB 231 cells and similar 
results were with MDA-MB 361 cells. My findings resemble other studies, such as the study 
conducted by Davaille et al and Moore et al. In Davaille et al.’s research they found that S1P has 
a dual opposing effect on hMF. It enhanced the cell proliferation of hMF by activation of S1PRs 
at nanomolar concentration and its apoptotic effect occurred at a micromolar concentration of 
S1P (Davaille et al., 2000). Moore et al. found that prolong exposure to 10 µM S1P induced 
apoptosis in hippocampal neurons. On the contrary, they found that prolong exposure to low 
levels of S1P (2 µM) did not cause any morphological change (Moore et al., 1999). To conclude, 
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in the present study I have demonstrated the opposite effects of S1P on two types of breast 
cancer cell the ER+ve / HER-2 +ve and ER-ve/ HER-2 –ve, suggesting, S1P exerts a dual effect 
on breast cancer cells.  
4.6. CHRONIC EXPOSURE WITH INTRA-TUMOURAL INJECTIONS OF SPHINGOSINE-
1-PHOSPHATE IS NON TOXIC 
Although sphingosine-1-phosphate is an endogenous substance and less likely to cause 
toxicity in vivo, its effects when given exogenously should be examined. Especially, it is 
important to examine the effects of long-term exogenously administrated S1P on major organs, 
such as the heart, kidney, and liver. However, in my study there was no excessive systemic 
exposure of S1P, because I gave S1P as intra-tumoural local injection; redistribution of S1P to 
the systemic circulation dose occur, but systemic exposure levels are significantly lower than 
levels following oral or intravenous administration, administration routes which demand much 
higher doses of the compound to achieve pharmacological active levels at the site of action. In 
addition, we used low doses of S1P, i.e., 1 µM/dose, which is similar to the normal body level 
(0.2- 0.9 µM). In my immunohistochemistry studies we found that chronic exposure of S1P is 
less likely to cause harm to the heart, liver and kidney (Figures 22, 23, 24, and 25).  
4.7. S1P INDUCED APOPTOSIS IN MDA-MB 361 BREAST CANCER CELLS BY 
CASPASE 3/7 INDEPENDENT PATTERN 
In Figure 9 and 11, I found that S1P caused less proliferation and less apoptosis as S1P 
concentration increased in the MDA-MB 361 cells and these results oppose each other. The 
explanation in this variation of S1P response in the MDA-MB 361 cells is that S1P may induce 
apoptosis in the MDA-MB 361 cells by caspase 3/7 independent pattern. In this study I used 
Caspase-Glo® 3/7 assay to determine the percent increase of cell apoptosis induced by S1P in 
the MDA-MB 361 cells and the results shows that S1P caused less apoptosis. There are many 
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mechanisms by which cells undergo apoptosis and in the MDA-MB 361 cells S1P could induce 
apoptosis by a different mechanism compared to the MDA-MB 231 cells.   
5. CONCLUSION 
Despite the improvement in breast cancer patient clinical outcomes due to the use of the 
current available therapies, the morbidity and mortality rate of breast cancer remains high. There 
is a need to find new ways to treat breast cancer. In the last decade, technological enhancements 
have improved our understanding of breast cancer biology. Based on this knowledge new 
medications were developed to target different pathways, which correlate with breast cancer 
development. Targeting the apoptosis pathway is one of the new strategies developed to treat 
breast cancer and sphingolipids play a vital role in controlling both cell apoptosis and 
proliferation processes. Studying agents such as S1P that can act on both apoptosis and 
proliferation may offer a new treatment option in the current breast cancer drug arsenal. The 
main objectives of this study were to examine the role that S1P play in breast cancer and its 
potential application in breast cancer treatment. In vitro studies (i.e., apoptosis, proliferation, 
cytotoxicity, and raman imaging) and in vivo studies (i.e., the MCF7 xenograft nude mice model) 
were designed to determine whether S1P is a useful therapeutic agent and a good target for breast 
cancer treatment and prevention and whether S1P is a good candidate for combination therapy. 
Addition of S1P to chemotherapeutic drug regimens may decrease the toxicity, through 
anticancer drug dosage reduction and reduce the possibility of drug resistance development. The 
major findings of this study were that: S1P enhanced the cytotoxicity of anti-cancer drugs against 
breast cancer depending on the following factors: the type of the breast cancer cell and the 
concentration of S1P used. In addition, I found that S1P was more potent against aggressive 
breast cancer cell lines compared with other type of breast cancer cells. Moreover, I found that 
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S1P shows selectivity to breast cancer cells at low doses. Using a low dose of S1P induced 
apoptosis in breast cancer cells without harming normal breast cells.  
6. FUTURE DIRECTIONS 
The future directions of this research are many. The first direction, the effect of S1P on other 
type of breast cancer cells, particularly, triple negative breast cancer cells needs to be examined. 
This can be done by performing similar in vitro studies, including apoptosis, proliferation, and 
cytotoxicity studies, as performed in my thesis work. In addition, the apoptotic effect of S1P on 
MDA-MB 361 cells needs further evaluation. In my work I used Caspase-Glo®3/7 assay but we 
need to conduct a different assay such as the DNA Tunnel assay. The second direction is to study 
the expression of SIPRs on different breast cancer cells types. This can be done by extracting 
mRNAs for the S1PRs, especially, S1PR1, S1PR2 and S1PR3 from breast cancer cells. After 
that, Quantitative RT-PCR should be performed. These three receptors are known to be involved 
in cell fate and migration and assessing their expression in breast cancer cells is important to 
clarify S1P functions and role in breast cancer. The third direction is to study the effect of S1P 
on breast cancer motility. S1P is known to affect cell motility dependent on S1PRs expression in 
cells and it is involved in malignant cells progression and metastasis. This can be done by 
performing chemotaxis motility assay and from this test the S1P effect on different type of breast 
cancer cells motility can be examined. The fourth direction is to evaluate the expression of the 
three enzymes that determine the S1P level, which are S1P-phosphatase, S1P-lyase and SK, on 
different type of breast cancer cells. The expressions of these enzymes determine the S1P effect 
on breast cancer cells. This can be done by extracting the mRNAs for these enzymes from breast 
cancer cells then performing Quantitative RT-PCR. The fifth direction is to elucidate the S1P 
intracellular target that triggers its apoptotic effect. My thesis work suggests that S1P induces 
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apoptosis and inhibits proliferation of breast cancer cells. However, the mechanism by which 
S1P induces apoptosis requires investigation. This can be done by performing Quantitative RT- 
PCR to examine the effect of S1P on different apoptosis pathways. Any alteration on the 
expression of the genes involved in the apoptosis may identify the mechanism. The expression of 
p21, p53, Bax and Bcl-2 may provide some answers. Once we detect the gene that is associated 
with S1P effect we can silence the gene and examine the impact on breast cancer cells. In 
addition, other intracellular functions of S1P need more clarification. The sixth direction is to 
uncover S1P’s role in the mechanism of drug resistance development. Some studies suggest the 
interaction of S1P with an efflux transporter, such as P-glycoprotein. S1P’s effect on P-gp needs 
further evaluation to clarify S1P role in drug resistance development in tumours. Over-
expression of P-gp and other efflux transporters in tumour cells is a major obstacle in cancer 
treatment and understanding S1P’s role may solve this major problem. This can be done by 
performing Quantitative RT-PCR to examine the effect of S1P on the expression of P-gp in 
different type of human breast cancer cells. The seventh direction is to find the causes of potent 
and consistence effect of S1P in aggressive breast cancer cells as compared with less aggressive 
breast cancers cells. Does the estrogen receptor or human epidermal growth factor expression 
interfere with S1P overall effect on different type of breast cancer cell? It is known that estradiol 
stimulate SK1 and increase the release of S1P through activation of ABCC1 and ABCG2 
transporters (Pyne & Pyne, 2010). The final direction, we need to examine the S1P effect in vivo 
alone or in combination with anti-cancer drugs. This can be done by evaluating S1P on different 
types of breast cancer xenograft nude mice models. For example, we could develop a triple 
negative breast cancer xenograft nude mice model and examine the effect of S1P alone or in 
combination with anti-cancer drugs, such as docetaxel, cyclophosphamide, or doxorubicin.  
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Figure 28. Animal study results. The mean weight of the mice (gm) ± SD of treated and control 
groups during the whole experiment (panel a). The tumour volume (mm
3
) ± SD of the treated 
and control group during the 21 days of the experiment (panel b). The tumour volume is 
significantly different between the control group and the group who received the combination 
therapy, while there was no significant difference between the control and the other group. For 
the data analysis a One-Way ANOVA followed by Tukey’s and Bonferroni’s multiple 
comparison tests was performed by using GraphPad Prism.    
 
 
a. 
b. 
